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Tissue stem cells balance fate decisions of self-renewal and differentiation to maintain
homeostasis over the lifetime of an organism, as well as to repair tissues upon injury and wounding.
Disrupting the balance between self-renewal and differentiation results in pathology: excessive
self-renewal at the expense of differentiation is associated with tumor initiation, whereas failure
to properly self-renew leads to stem cell exhaustion and aging. Stem cell fate is under tight
regulation by the surrounding microenvironment, or niche, which includes neighboring cell types,
signaling molecules, extracellular matrix, and nutrients. While the role of stromal cells and the
signals they produce has been extensively studied with regards to control of stem cell fate,
relatively little known is about how tissue stem cells integrate extracellular nutrient availability
with fate decisions. Moreover, while intracellular metabolic pathways have been shown to regulate
the balance of self-renewal and differentiation, it remains unknown whether or not endogenous
metabolic pathways or nutrient availability predispose stem cells towards transformation or control
their responses to tissue injury.
Here, I address these questions in epidermal stem cells (EpdSCs), which maintain integrity
of the skin barrier over an organism’s life. EpdSCs are a cell of origin for squamous cell
carcinomas (SCCs), amongst the most common and threatening malignancies worldwide.
Additionally, EpdSCs of the interfollicular epidermis (IFE) and hair follicle (HF) respond to
injuries in the skin barrier to repair the breach. First focusing on tumor initiation, I find oncogenic
EpdSCs are serine auxotrophs, whose growth and self-renewal require abundant exogenous serine.
When extracellular serine is limited in vitro and in vivo, EpdSCs activate de novo serine synthesis,

which in turn produces the metabolite α-ketoglutarate (αKG). αKG stimulates terminal
differentiation via activation of αKG-dependent dioxygenases that remove the repressive histone
modification H3K27me3, which otherwise promotes EpdSC self-renewal. Accordingly, serine
starvation or enforced αKG production antagonizes SCC initiation and growth. Conversely,
blocking serine synthesis or repressing αKG-driven demethylation facilitates malignant
progression in vivo.
Finally, I extend these findings to stem cell responses to tissue injury. In the epidermis,
abrasion of the IFE activates HFSCs to repair the breach, which is associated with transient
hyperproliferation, migration and activation of a plasticity program termed lineage infidelity
wherein HFSCs undergo a fate switch to become IFE-SCs, fueling regeneration of a non-cognate
tissue. I find that environmental serine restriction accelerates HFSC-mediated wound repair, which
I link specifically to acceleration of stem cell plasticity and acquisition of IFE fate. Altogether,
these findings reveal that extracellular serine is a critical determinant of EpdSC fate and provide
insight into how nutrient availability is integrated with stem cell fate decisions during tumor
initiation and tissue repair.
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CHAPTER ONE: INTRODUCTION
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1.1 INTRODUCTION
Development and homeostasis of multicellular organisms depends on cells acquiring and
maintaining the correct fate at the right place and time. Cell fate determination, wherein less
differentiated cells progressively acquire specific fates and functions, is essential for proper
embryogenesis and normal development. Even in postnatal life, proper cell fate determination is
critical for maintenance of tissue homeostasis, which requires stem cells to balance self-renewal
and differentiation. In both the embryo and postnatal tissues, cell fate determination depends both
on inductive signals from the environment and the competence of cells to respond appropriately
to these signals1–3. The landmark discovery of the Spemann-Mangold organizer demonstrated that
a collection of embryonic cells is sufficient to re-pattern fate determination programs in amphibian
embryos4. Early in development, factors secreted by the organizer can induce non-neural tissue to
adopt a neural fate, but this plasticity is lost as development progresses. In postnatal life, inductive
signals triggered by threats to tissue integrity can drive stem cells to mount proliferative programs
to restore homeostasis3. Even differentiated cells can be coaxed to respond to inductive signals
when needed: for example, upon injury to the intestinal stem cell pool, differentiated Paneth cells
are able to de-differentiate into stem cells, facilitating intestinal repair5. These examples highlight
how cell fate changes require precise environmental cues, which interact with cell-state specific
factors, to shape appropriate cellular outcomes. Accordingly, dysregulation of either extracellular
cues or their downstream intracellular responses compromise cell fate programs and results in
diseases ranging from birth defects to cancer

2,3

. Consequently, understanding the molecular

regulation of cell fate decisions is critically important for understanding the mechanistic basis of
both normal physiology and disease states.
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The transcriptional program of a cell is a key determinant of cell identity. The paramount
importance of transcriptional programs to cell identity is perhaps best highlighted by the
reprogramming of fully differentiated cells to pluripotent stem cells simply by expressing four key
pluripotency transcription factors6. Thus, understanding the mechanisms that regulate a cell’s
transcriptional output is key to understanding cell fate decisions. Transcriptional changes can be
facilitated by remodeling a cell’s chromatin landscape, and a large body of work has focused on
the role of chromatin regulation in cell fate decisions 1–3,7. In particular, chemical modifications on
DNA and histones provide a critical avenue for cells to control activation of gene expression
programs. These chemical modifications are derived from intermediates of cellular metabolism,
most notably S-adenosylmethionine and acetyl-CoA, which serve as the donors for methylation
and acetylation modifications, respectively. Enzymes that remove these modifications often also
require metabolites as critical co-substrates. Accordingly, fluctuations in the availability of key
metabolites that modulate activity of chromatin-modifying enzymes are postulated to contribute
to transcriptional regulation by shaping the chromatin landscape 8–10.
Intracellular metabolite levels are responsive to both cell-intrinsic metabolic pathway
activity as well as extrinsic cues from the microenvironment, including growth factors and nutrient
availability. Many inputs, including tissue lineage, proliferative status and nutrient availability,
collectively determine the metabolic demands of individual cells11,12. Accordingly, recent studies
highlight that cell-type specific metabolic demands influence cellular proliferation and fate in
response to microenvironmental changes, including changes in key nutrients

13–15

. Emerging

evidence additionally suggests that tissues experience distinct nutrient microenvironments, and
that heterogeneity in extracellular nutrients can control cell fate by controlling the availability of
metabolites that regulate the chromatin landscape 14,16–20. In this manner, intracellular metabolites
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are emerging as critical components of cell fate determination programs, capable of integrating
extracellular nutrient status and intracellular biochemical demands to influence transcriptional
networks and cell fate decisions.
Here, I review the proposed mechanisms by which select intracellular metabolites integrate
environmental inputs to shape pathways determining lineage specific cell fates . I focus on
metabolic intermediates of the tricarboxylic acid (TCA) cycle, a central regulatory hub of nutrient
metabolism within cells. Multiple extracellular nutrients can feed into the TCA cycle, although in
proliferating cells the major TCA cycle fuels are glucose and glutamine (Fig. 1.1a). Several
intermediates of the TCA cycle, including α-ketoglutarate (αKG), succinate, and fumarate have
been shown to regulate gene expression programs in various contexts

8,21

. Thus, the TCA cycle

may integrate both extracellular nutrient availability and downstream transcriptional changes
during cell fate changes. In particular, I discuss evidence that regulation of gene expression and
cell fate by TCA cycle metabolites is context-dependent, with metabolites acting both upstream
and downstream of lineage specific signaling and specification programs to shape cell fate. Finally,
I discuss how nutrient availability creates permissive environments for cell fate outcomes by
regulating intracellular metabolic pathways.

4

Fig. 1.1: Metabolic regulation of αKG-dependent dioxygenases. a, Schematic of key pathways
involved in synthesis and break down of αKG, 2HG, fumarate and succinate. Enzymes directly
involved in αKG metabolism are shown in blue, those involved in 2HG, fumarate and succinate
metabolism are shown in red. b, Generalized schematic of αKG-dependent dioxygenase (also
known as 2-oxoglutarate dependent dioxygenase or OGDD) action on your favorite target.
Dioxygenases cataly ze net demethylation or hydroxylation reactions using αKG and molecular
oxygen as co-substrates and producing succinate as a by-product. Vitamin C, oxygen and αKG
have been shown to promote dioxygenase activity, whereas succinate, fumarate and 2HG have
been shown to suppress their activity. c, Enzymatic assays provide potential insights into metabolic
regulation of dioxygenase catalytic activity. In this example, dioxygenase B is expected to be
sensitive to physiological fluctuations in αKG concentrations, whereas dioxygenase A will be less
sensitive. However, it remains unclear what true physiological αKG concentrations are, given that
dioxygenases may be sensitive to compartmentalized metabolite pools.

1.2 αKG-DEPENDENT DIOXYGENASES AS METABOLIC MEDIATORS OF CELL
FATE CONTROL
Mechanistically, changes in TCA cycle metabolites are postulated to affect cell fate by
regulating activity of α-ketoglutarate dependent dioxygenases 22,23. The family of αKG-dependent
dioxygneases comprises over 60 enzymes, including Jumonji C-domain lysine demethylases
(JmjC-KDMs),

which

demethylate

histones,

Ten-Eleven

Translocation

(TET)

DNA

methylcytosine oxidases, and prolyl hydroxylases, which control collagen biogenesis and hypoxiainducible factor (HIF) stability. TCA cycle intermediates serve both as critical co-substrates and
competitive inhibitors of αKG-dependent dioxygenases: the enzymes consume αKG and
5

molecular oxygen as part of their reaction cycle, yielding succinate and carbon dioxide8. αKGdependent dioxygenases are inhibited by other TCA cycle metabolites including succinate and
fumarate, as well as the related metabolite 2-hydroxyglutarate (2HG), which can exist in cells as
both a D and L enantiomer (Fig. 1.1b). Mutations in several of the enzymes that are involved in
the production and breakdown of these metabolites, including isocitrate dehydrogenase (IDH1 and
IDH2), succinate dehydrogenase (SDH), and fumarate hydratase (FH) have been shown to be
drivers in cancer by disrupting normal cell fate decisions

21

(Fig. 1.1a). Even absent these

mutations, however, intracellular abundances of aKG, succinate, fumarate and 2HG have been
shown to regulate cell fate, including in stem cells, immune cells, and cancer cells 8,21.
The observation that TCA cycle metabolites can control αKG-dependent dioxygenases and
cell fate raises major questions, including how a non-specific signal such as TCA cycle
intermediate abundance can lead to a specific outcome in cell fate. One possibility is that the effect
of a change in metabolite abundance is read out by a cell based on the relative affinity of
dioxygenases for that metabolite. Briefly, the Km of an enzyme for a particular substrate must be
within the range of physiological fluctuations in concentration of that substrate in order for the
enzyme’s activity to be significantly affected by changes in substrate levels 8,10 (Figure 1.1c). In
vitro enzymatic assays suggest that the Km of αKG-dependent dioxygenases for αKG are in the
low (~1-50) micromolar range, whereas the Ki and IC50 of succinate, fumarate, and 2HG are in the
upper micromolar to low millimolar range 24. Even within these ranges, however, there is evidence
for differential effects of metabolites on dioxygenase activity 22,24,25. For example, in vitro studies
suggest that (L)- but not (D)-2HG inhibits prolyl hydroxylase function

22,25

, and even closely-

related dioxygenases can exhibit vastly different affinity for the same metabolite 24,26. Thus, the
response to a metabolite may be contingent upon the enzymatic properties of dioxygenases, and it

6

will be of major interest in the future to understand whether the expression patterns of
dioxygenases with varying affinity for metabolites provides a biochemical rationale for specific
outcomes driven by metabolic perturbations.
Nevertheless, there are several important limitations to cell-free systems in understanding
metabolic control of cell fate. First, kinetic constants determined in simplified settings in vitro may
not reflect enzyme behavior in a complex environment in vivo. Second, current approaches to
measure metabolite concentrations provide information on whole cell or tissue abundances, while
chromatin modifying αKG-dependent dioxygenases may be sensitive only to nucleo-cytosolic
levels of metabolites, where substrates may be more (or less) limiting

27,28

. Suggestively, cancer

associated IDH mutations (mtIDH), which convert αKG to 2HG, occur in both cytosolic IDH1 and
mitochondrial IDH2, but mtIDH1 traditionally drives lower production of 2HG than mtIDH2.
However, 2HG production by mtIDH1 is increased upon ectopic targeting to the mitochondria,
potentially reflecting limited substrate availability in the cytosol

28

. Whether or not nucleo-

cytosolic dioxygenases compete for a limited pool of αKG remains to be explored.
An additional challenge in understanding how changes in select TCA cycle metabolites
may coordinately influence cell fate is the fact that multiple dioxygenase-sensitive marks are often
affected by metabolic changes 29–32. For example, succinate and fumarate accumulation in cancer
cells is linked to HIF stabilization and hypermethylation of DNA as well as multiple histone lysine
residues

31,33,34

. The ability of a single metabolite to influence multiple relevant pathways

highlights the importance of these molecules but poses a challenge in understanding which changes
represent biologically relevant, primary responses. For example, fumarate accumulation in FH
deficient cells was thought to drive tumorigenesis in the kidney via inhibition of PHDs and
subsequent stabilization of HIFs. However, double knockout of HIF1α and HIF2α did not prevent

7

FH-loss induced renal cyst formation, which was instead dependent on hyper-activation of NRF2
signaling driven not by fumarate-mediated inhibition of αKG-dependent dioxygenases but rather
by direct covalent modification of reactive cysteines on KEAP1, a major negative regulator of
NRF2 35. Indeed, many studies provide evidence that metabolites regulate cell fate decisions and
dioxygenase-sensitive marks but remain correlative with regards to the precise mechanisms by
which these effects are mediated.
The most rigorous approach to studying metabolic control of cell fate will involve both
cell-free biochemical studies and genetic experiments in relevant in vivo systems. This combined
approach recently revealed a critical role for molecular oxygen in muscle differentiation. αKGdependent dioxygenases consume oxygen as part of their reaction cycle, and therefore may directly
respond to hypoxia. The authors found that hypoxia impaired myogenic differentiation by
inhibiting the αKG-dependent H3K27me3 demethylase UTX, which has a low in vitro oxygen
affinity. Notably, the closely related H3K27me3 demethylase, JMJD3, has relatively high oxygen
affinity and was not sensitive to hypoxia. Mutagenesis of key residues in UTX’s catalytic domain
to resemble that of JMJD3 was sufficient to increase oxygen affinity and restore differentiation in
hypoxia26. It will be critical in the future to perform analogous experiments to manipulate
sensitivity to fluctuations in TCA cycle metabolites so as to identify primary responders in cell
fate decisions linked to these metabolites.

1.3 CANCER ASSOCIATED MUTATIONS HIJACK METABOLIC CONTROL OF CELL
FATE
The identification of recurrent oncogenic mutations in metabolic enzymes sparked interest
in the role of metabolites as drivers of cell fate decisions. Mutations in IDH1 and IDH2 lead to
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accumulation of (D)-2HG, while mutations in SDH components and FH lead to accumulation of
succinate and fumarate, respectively31,36,37. 2HG, succinate, and fumarate are collectively known
as oncometabolites, competitively inhibit αKG-dependent dioxygenases, and are often suggested
to exert similar functions in blocking stem cell differentiation 30,31,33,34,38.
In vitro differentiation of mesenchymal, hepatic, hematopoietic and neural progenitors are
all suppressed by expression of mtIDH1/2 or 2HG treatment alone 22,30,39,40. In vivo, expression of
mtIDH in the brain, bone marrow and liver all lead to expansion of resident progenitor populations
and suppression of terminal differentiation

39,41,42

. SDH-deficient paragangliomas arise in the

oxygen sensing carotid bodies, a neural crest derived organ, and Sdhd loss is associated with
carotid body hypertrophy and reduced differentiation

43,44

. Together, these studies suggest that

inhibitory metabolites act by suppressing the competence of stem cells to respond to appropriate
differentiation stimuli, such that stem cell division is skewed towards self-renewal.
In classic models of cell fate induction, cellular competence to respond to inductive signals
for fate changes can be suppressed by direct inhibitors of that signaling pathway. For example, in
the developing skin spatially restricted expression of Wnt inhibitors leads to distinct fate outcomes
of Wnt-responsive and non-responsive cells45,46. By analogy, the pervasive observation that
oncometabolites block differentiation across multiple lineages raises the possibility that αKG
could be an inductive signal for adult stem cell differentiation. In support of this model, ascorbate,
which promotes αKG-dependent dioxygenase function, drives hematopoietic stem cell (HSC)
differentiation and suppresses leukemogenesis47,48. Exogenous αKG also promotes cytokineinduced HSC differentiation49, and αKG is necessary and sufficient for effector T-cell
differentiation50,51. Notably, the effects of αKG extend beyond tissues that are prone to
transformation by oncometabolites. In both intestinal and epidermal stem cells, αKG is sufficient
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for stem cell differentiation and suppressed tumor initiation and progression14,52. The effects of
αKG extend to transformed cells: in pancreatic cancer cells, p53 restoration drives αKG-dependent
differentiation, and αKG alone is sufficient to recapitulate the effects of p5353. When tested in
these settings, succinate showed little effect except under conditions of αKG accumulation14,53,
consistent with αKG acting as an inductive signal and its antagonists establishing repressive
thresholds for cell fate changes. In this manner, mutations in metabolic enzymes that lead to
accumulation of 2HG, succinate and fumarate may be akin to mutations in key tissue specific
signaling pathways that normally act to restrain stem cell self-renewal.

1.4 CANCER ASSOCIATED MUTATIONS SUGGEST LINEAGE SPECIFIC EFFECTS
OF METABOLITES
Despite evidence that 2HG, succinate and fumarate act via similar mechanisms, mutations
that drive accumulation of these oncometabolites occur in tumors of distinct lineages. For example,
acute myeloid leukemia (AML) and gliomas harbor IDH but not SDH and FH mutations, whereas
the opposite is true for renal cell carcinoma and neuroendocrine tumors31,54,55. The nonoverlapping patterns of mutations suggest tissue-specific functions of these metabolites, despite
their similar effects in biochemical assays. Thus, it is critical to understand how metabolites act in
the context of the particular cohort of lineage specific signals and factors experienced by individual
cells. Below, I discuss evidence that the response to a metabolite is lineage specific and in
subsequent sections I review potential mechanisms by which lineage factors and environmental
inputs might shape the cellular response to individual metabolites. Collectively, these studies raise
two related but separate points: specific metabolites may be required for particular chromatin
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changes and cell fate decisions, and different lineages may exhibit distinct responses and
sensitivities to metabolites.
The potential for context-specific effects of metabolites has been best studied in
hematopoiesis, which is fueled by HSCs. Consistent with an oncogenic function for 2HG,
expression of mtIDH1/2 or treatment with (D)-2HG alone leads to increased proliferation and selfrenewal of HSCs and other hematopoietic progenitors at the expense of proper differentiation in
vitro and in vivo23,38,41. Accordingly, mtIDH2 cooperates with additional oncogenic hits to drive
leukemogenesis in mice 56. In contrast, both SDH and FH loss lead to impaired HSC maintenance
and function. Moreover, FH loss suppressed, rather than supported, leukemic transformation 57,58.
One possible explanation for disparate effects of IDH, SDH and FH mutations is that SDH
and FH are components of the core oxidative TCA cycle, whereas IDH1 and IDH2 are not. Thus,
it may be that HSCs are unable to cope with TCA cycle truncation, which requires distinct
metabolic adaptations 59. A second potential reason for this discrepancy, however, is the unique
effects of (D)-2HG versus succinate and fumarate on αKG-dependent dioxygenases. Whereas
mtIDH1/2 inhibited both TET2-mediated DNA demethylation and JmjC-KDM-mediated histone
demethylation, FH loss in HSCs only inhibited histone demethylation

38,41,58

. Fumarate

additionally functions to modify reactive cysteine residues, and thus is likely to exert functions
independent of αKG-dependent dioxygenases

35,60

. Altogether, these studies support distinct

effects of succinate, fumarate and 2HG accumulation on HSC behavior.
In AML, multiple neomorphic mutations in IDH1 and IDH2 occur, all of which are
sufficient to induce (D)-2HG and block hematopoietic differentiation 23,38,41. As noted above, 2HG
accumulation is thought to play a major role in suppressing HSC differentiation by antagonizing
TET2 function. This notion has been bolstered by the observation that IDH1/2 mutations in AML
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are mutually exclusive with TET2 mutations, and TET2 loss of function phenocopies mtIDH
expression 23,38. Even within the hematopoietic lineage, however, IDH mutations may exert distinct
effects. For example, IDH mutations occur only at R172 of IDH2 in angioimmunoblastic T-cell
lymphoma (AITL), where they co-occur with TET2 mutations. IDH2 R172 mutants produce
significantly more 2HG than other mutants, and only IDH2 R172 mutant expression disrupts Tcell differentiation in mouse models61. These data suggest that 2HG dosage may have cell-type
specific effects and that the same metabolite can exert distinct effects at different stages of a
developmental trajectory. Thus, gaining an understanding of how metabolites cooperate with
lineage specific transcription factors and signaling pathways may provide insight into why
metabolites exhibit cell-type specific effects.

1.5 METABOLIC INTERACTION WITH LINEAGE SPECIFIC TRANSCRIPTION
FACTORS
Studies highlighting the context-specific effects of oncometabolites indicate that
metabolites will likely regulate cell fate decisions in a tissue-specific manner. Given the abundance
of literature on the critical role transcription factors (TFs) and cell-type specific enhancer
landscapes play in establishing and maintaining cell identity, it is likely that effects of metabolites
will vary according to their ability to interact with lineage specific transcriptional machinery. In
this section I discuss two potential mechanisms by which metabolites may regulate cell fate
changes: first, I review evidence that metabolites can directly control TF abundance and
expression; and second, I review data suggesting that metabolites regulate TF activity by globally
modulating co-activator function. Since different cell fate changes are likely to rely on distinct TF
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and co-activator cohorts, these data may provide an explanation for lineage specific effects of
metabolites.
Limited evidence suggests that metabolites may act upstream of lineage TFs. In the liver,
mutant IDH1 expression blunts progenitor differentiation into hepatocytes by silencing the master
TF HNF4α39. In intestinal tumor organoids, αKG is sufficient to suppress activation of the master
intestinal stem cell regulator β-catenin and induce differentiation52. Despite these observations and
correlations with changes in DNA and histone methylation at TF promoters and target gene loci,
the exact mechanisms by which metabolites affect expression of specific TFs are not well
understood.
Appealing mechanisms by which metabolites could act upstream of master lineage
regulators are via post-transcriptional and post-translational regulation of TF expression. The RNA
demethylases FTO and ALKBH5, which demethylate N6-methyladenosine (m6A), are αKGdependent dioxygenases. m6A destabilizes transcripts and has been found to regulate expression
of key TFs in embryonic stem cells (ESCs) and HSCs 62–64. Moreover, it was recently shown that
2HG suppresses FTO activity in leukemia cells, leading to decreased expression of the lineage TF
CCAAT enhancer binding protein α (C/EBPα), which enforces normal HSC quiescence and
myeloid differentiation 65–67. In this manner, direct metabolic regulation of key TF expression may
enable specific cell fate outcomes.
Metabolites also exert post-translational control over TFs, as exemplified by the dominant
role of αKG-dependent prolyl hydroxylation in the control of HIF1α stability

25,33

. Studies in

macrophages recently uncovered the ability of αKG-dependent prolyl hydroxylases to regulate
other TFs during cell fate decisions. These studies revealed that αKG is necessary for antiinflammatory M2 polarization and sufficient to suppress pro-inflammatory M1 polarization. While
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the effects of αKG on M2 polarization required the H3K27me3-demethylase JMJD3, αKG
suppressed M1 polarization by inhibiting the master inflammatory TF NFkB via prolylhydroxylase-dependent modification of its activator IKKβ. Accordingly, a hydroxylation-dead
IKKβ mutant rendered M1 polarization resistant to αKG 68. Thus, exploring post-transcriptional
and post-translational regulation of TFs by αKG-dependent hydroxylases may identify new layers
of regulation by which metabolites can induce cell fate changes (Fig. 1.2a).
Transcription factors can regulate gene expression by recruiting co-activators and/or corepressors to target loci

7

. Co-activators, including TETs and H3K27me3 demethylases

JMJD3/UTX, require αKG as a co-substrate, raising the possibility that metabolites function in
cell fate decisions by regulating TF function via potentiating or suppressing co-activator activity
(Fig. 1.2b). This model has been best studied in mouse embryonic stem cells (ESCs). ESCs can be
maintained in vitro in a heterogeneous state of metastable pluripotency or as a homogeneous
population of cells in the naïve ground state of pluripotency via culture in specific media
formulations. The naïve ground state of pluripotency is intrinsically associated with an
accumulation of αKG at the expense of succinate, which is reflected by an increase in the
αKG/succinate ratio, due to reduced αKG catabolism in the TCA cycle13,29. Notably,
supplementing metastable ESCs with αKG is sufficient to facilitate TET and UTX/JMJD3mediated DNA and histone demethylation, respectively, and increase pluripotent self-renewal29.
The ground state of pluripotency is characterized by a robust TF network, whose action is
facilitated in part by recruitment of TET1/2 to key pluripotency loci

69–71

. This robust

transcriptional network enables naive, but not metastable, ESCs to maintain growth and
pluripotency upon inhibition of the co-activator Brd4, which binds acetylated histones to activate
transcription and is usually essential for maintenance of gene expression programs72. The ability
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of pluripotency TFs to confer Brd4 independence and sustain self-renewal is sensitive to metabolic
perturbations, since glutamine starvation – which depletes αKG – blunts expression of key
pluripotency genes and ascorbate enhances self-renewal in the presence of Brd4 inhibitors
Intriguingly, mtIDH AMLs are highly sensitive to Brd4 inhibition

56

69

.

. Whether or not this

sensitivity is due to decreased ability of αKG-dependent dioxygenases to function downstream of
master hematopoietic TFs upon 2HG accumulation remains to be explored but would be consistent
with the data in ESCs.
Core pluripotency TFs are known to drive their own expression, creating a positive
feedback loop, and can remain bound to target genes even upon induction of differentiation
stimuli73,74. This enables ESCs to revert to pluripotency upon withdrawal of differentiation stimuli
so long as these key TFs remain chromatin bound 74. Thus, if αKG acts by promoting pluripotency
TF function, loss of these TFs from chromatin late in differentiation would blunt the effects of
αKG. Consistently, αKG can only sustain ESC pluripotency when provided early after a
differentiation stimulus, when expression of pluripotency TFs remains high 75. Differentiation is
associated with a decrease in αKG that coincides with the loss of pluripotency TFs; conversely,
overexpression of key pluripotency factors such as NANOG or activated STAT3 are sufficient to
increase αKG, suggesting that αKG accumulation may be a component of the feed-forward loop
of the pluripotency network 13,75.
Notably, αKG doesn’t always enhance ESC self-renewal. In more committed pluripotent
cells such as human ESCs and mouse post-implantation epiblast ESCs, however, αKG actually
facilitated differentiation, which was antagonized by succinate

76,77

. The differential response to

αKG may reflect either the more committed state of human and mouse epiblast ESCs or the
particular differentiation stimuli used in each condition. Alternatively, αKG may exert different
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outcomes as a result of distinct requirements for self-renewal vs. differentiation in different cell
states, either due to different cohorts of TFs or different required changes in chromatin to achieve
a cell state change. Notably, the naïve and more committed, primed states of pluripotency have
dramatically different levels of DNA methylation

78

, and thus may have different sensitivity to

metabolic perturbations that favor demethylation. Given that αKG can influence both TF
expression directly and function indirectly, metabolites are likely to play numerous roles in
particular cell fate decisions, depending on the specific requirements of that cell state.
Recent evidence suggests that oncometabolites also can act by blunting co-activator action
at lineage specific genes. For example, during muscle differentiation the master TF MyoD recruits
H3K9me2/3 demethylases to target loci to promote expression. Accordingly, mtIDH1 expression
suppresses MyoD-mediated differentiation, which is rescued by genetic inhibition of H3K9
methyltransferases. Whereas normal myogenic differentiation is accompanied by selective
hypomethylation of H3K9 at myogenic targets, mtIDH1 expression drives global, apparently nonselective increases in H3K9me3 79. These results support a model wherein 2HG accumulation in
myoblasts establishes a global chromatin landscape that is incompatible with differentiation due
to inhibition of H3K9 demethylases, whereas locus specificity during differentiation is achieved
by TF recruitment of co-activators. Consistently, work in neural, mesenchymal and hematopoietic
cells shows that IDH mutations render stem cells unable to appropriately respond to differentiation
stimuli, although the interaction between master TFs, co-activators and metabolites remain to be
explored in these settings

23,30,38,40

. Thus, the ability of metabolites to regulate specific cell fate

changes is likely due to the combinatorial effects on lineage specific factor expression and
function, and gaining a detailed understanding of context-specific effects of metabolites will likely
require integration of these multiple regulatory nodes.
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Fig. 1.2. Potential mechanisms of metabolic control of cell fate. a, αKG-dependent
dioxygenases can directly impact expression of key transcription factors (KTFs) both by regulating
mRNA methylation and protein hydroxylation, both of which trigger target degradation. b,
Metabolites can regulate TF function by influencing co-activator function, a subset of which are
αKG-dependent dioxygenases. Transcription factors recruit co-activators such as TETs and KDMs
to target loci in order to locally remodel chromatin. c, Metabolites can impact enhancer function
and long range chromatin interactions by controlling CTCF binding to DNA, which is suppressed
by DNA methylation. αKG enforces TAD architecture in cells by facilitating CTCF binding,
whereas 2HG, succinate and fumarate disrupt TAD architecture. In the presence of CTCF, a celltype specific active enhancer drives expression of your favorite gene-A (YFG-A), whereas YFGB is suppressed. Upon loss of CTCF binding, however, TAD boundaries are disrupted and the
active enhancer drives expression of YFG-B.
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1.6 METABOLIC CONTROL OF LINEAGE SPECIFIC ENHANCERS
A key component of cell fate decisions involves TF-mediated establishment and binding
of cell type specific enhancers 80. Active enhancers are marked by acetylation of H3K27 and can
be suppressed by H3K27me3 and DNA methylation 81. Accordingly, metabolic regulation of αKGdependent dioxygenases can directly regulate enhancers. For example, FH deficient renal cells
exhibit increased DNA and H3K27 methylation at a putative enhancer for the microRNA cluster
mIR-200. Fumarate-mediated enhancer methylation suppressed the anti-metastatic miR-200
cluster, activating the epithelial-mesenchymal transition (EMT). Interestingly, exogenous αKG
reversed fumarate-induced EMT, suggesting that ongoing αKG-dependent dioxygenase activity
may be required for maintenance of the epithelial phenotype 82.
Recent studies profiling three-dimensional chromatin landscapes and the ubiquitously
expressed transcription factor CCCTC-binding factor (CTCF) have provided additional insights
into the interactions between metabolites and enhancers. The genome is organized into discrete
regulatory units called topologically associated domains (TADs), whose boundaries are
established by CTCF binding 83. Enhancers preferentially drive expression of genes within their
own TADs; accordingly, CTCF loss increases inter-boundary interactions at the expense of intraboundary interactions, thereby modifying enhancer-promoter contacts and altering gene
expression83. DNA methylation is emerging as a critical barrier to CTCF binding and TAD
regulation that is susceptible to metabolic perturbation

83

. In both mtIDH gliomas and SDH-

deficient gastrointestinal stromal tumors, hypermethylation of CTCF binding sites is associated
with increased interactions between key receptor tyrosine kinase (RTK) genes and constitutive
lineage-specific enhancers normally outside of their domains, driving RTK expression. Deletion
of key CTCF binding sites alone phenocopied the effects of mtIDH or SDH loss on RTK
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expression 84,85. Similarly, experiments performed in a human ESC model of glioma demonstrated
that mtIDH suppressed differentiation by disrupting CTCF binding, leading to reduced interaction
of the SOX2 locus with an active enhancer 86. Collectively, these studies demonstrate the potential
of oncometabolites to influence enhancer activity towards target genes (Fig. 1.2c).
Intriguingly, CTCF is ubiquitously expressed, and many of its binding sites are shared
between different cell types 87. Therefore, metabolic regulation of CTCF per se is not sufficient to
result in tissue specific effects; rather, the particular enhancer landscape of a cell will play a key
role determining the transcriptional outcomes of altered CTCF binding. For example, αKG induces
increases in CTCF binding at overlapping loci in ESCs and T-cells, but cell-type specific changes
in gene expression. In T-cells, αKG supports effector T-cell differentiation by increasing
interactions of IL-2 target genes with active T-cell enhancers. Although αKG also increases CTCF
binding in the vicinity of key ESC genes in T-cells, these genes are not transcriptionally induced
because they lack active enhancers in T-cells50. Altogether, these data support a model wherein
αKG and its inhibitors contribute to cell fate regulation by controlling three-dimensional chromatin
architecture, but specific cell fate outcomes are driven by the enhancer landscape of a cell. Most
likely, all of these factors can converge enabling metabolites regulate cell fate changes by coregulating chromatin architecture and TF function.

1.7 NUTRIENTS REGULATE αKG-DEPENDENT DIOXYGENASES
In vivo cell fate changes do not occur in isolation, but rather in a spatiotemporally defined
manner that is under the control of a cell’s microenvironmental milieu, or niche3. Many niche
derived signals can induce changes in intracellular metabolism. For example, growth factor
signaling acutely increases nutrient uptake, and stromal cells can provide metabolic support to
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stem cells by directly providing nutrients88,89. Additionally, the nutrients supplied to a tissue may
also influence cell fate by controlling intracellular metabolite abundance. Stem cells of multiple
tissues, including those of the blood, brain and skin are in close proximity to the vasculature,
suggesting that their nutrient microenvironment may be closely regulated via control of blood
supply and drainage 90–92. Given recent evidence that the extracellular nutrient milieu may vary in
a tissue-specific manner

16,93

, I discuss the possibility that nutrient availability within stem cell

niches could contribute to cell fate decisions through αKG-dependent dioxygenases (Fig. 1.3).
Oxygen. How cells adapt to hypoxia has been thoroughly reviewed elsewhere 94, and here
I highlight how αKG-dependent dioxygenases contribute to the cellular response to changes in
oxygen availability. While all αKG-dependent dioxygenases consume oxygen, only a subset have
sufficiently low affinity for oxygen to be limited by physiological levels of hypoxia 26. However,
hypoxic conditions, which induce intracellular acidification and high intracellular NADH/NAD+
favor promiscuous reduction of αKG to (L)-2HG by lactate dehydrogenase and malate
dehydrogenase 95,96. This rise in (L)-2HG, which inhibits most αKG-dependent dioxygenases more
potently than (D)-2HG, is necessary and sufficient for hypoxic hypermethylation of histones in
certain contexts 97. Collectively, these findings suggest that hypoxia may block αKG-dependent
dioxygenase activity through multiple mechanisms.
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Fig. 1.3. Niche regulation of αKG-dependent dioxygenases. Summary of potential regulators
within the stem cell niche of stem cell dioxygenase activity. αKG is largely derived from
glutamine, whereas serine and valine have been shown to suppress intracellular αKG levels.
Hypoxia directly antagonizes dioxygenase activity and facilitates production of 2HG from αKG.
Finally, the role of niche cells in αKG-dependent dioxygenase activity has yet to be explored but
is a potential regulator, as many stem cells reside in proximity to the vasculature and stromal cells
may provide nutrients to stem cells and/or compete with stem cells for nutrients within the niche.

Intriguingly, many stem cells including neural and hematopoietic stem cells reside in
hypoxic niches and can be regulated by HIF1a signaling 98–103. Notably, malignant ependymomas,
derived from hypoxic fetal neural precursors, require hypoxia to proliferate due to metabolic
requirements to maintain histone methylation and acetylation

104

. Whether or not metabolic

responses to hypoxia also contribute to normal stem cell behavior remains an open question. In
particular, hypoxia-induced 2HG could create a non-permissive environment for differentiation,
thereby coupling hypoxic niches to homeostatic stem cell self-renewal. While the majority of
HSCs reside in hypoxic peri-sinusoidal niches, some studies report a small percentage of
progenitors in well-oxygenated peri-arteriolar regions 105,106. Whether these HSCs are functionally
22

distinct in their ability to differentiate remains to be seen, but an intriguing possibility is that 2HG
levels would decline upon migration to better perfused niches, enabling differentiation. In this
model, IDH1/2 mutations would effectively uncouple HSC differentiation from niche regulation
via constitutive 2HG production. Studying the role of oncometabolites and αKG in tissue stem
cells experiencing physiological hypoxia will be an interesting area of research in the future.
Amino acids. In most proliferating cells in vitro, glutamine is the major contributor to the
carbon backbone of the TCA cycle. Glutamine is first deamidated to glutamate, which is then
deaminated to αKG via transaminase reactions or glutamate dehydrogenase. Accordingly,
manipulating extracellular glutamine levels has been shown to regulate TCA cycle metabolites,
cell fate, and proliferation

21,107

. As discussed earlier, reduced catabolism of glutamine-derived

αKG in the TCA cycle enables naïve mouse ESCs to maintain an elevated αKG/succinate ratio
and to proliferate in the absence of glutamine 13,29. Accordingly, glutamine has two distinct roles
in regulating ESC fate. Transient glutamine withdrawal selects for ESCs with enhanced selfrenewal due to death of more committed cells. However, because glutamine is the major source of
αKG, prolonged glutamine starvation decreases ESC self-renewal. Re-supplementation of
glutamine after a transient withdrawal therefore enables naïve ESCs to recover expression of key
pluripotency markers 13.
Glutamine is also a key regulator of αKG abundance and cell fate in adult tissues. In
macrophages, glutamine starvation blunts M2 polarization and favors a pro-inflammatory
phenotype, which can be reversed by αKG supplementation 68. Similarly, glutamine starvation in
T-cells prevents effector differentiation, which can be restored via αKG treatment. Glutamine
starved or (L)-2HG treated T-cells adopt a memory T-cell fate, a subset of which may have stem
cell properties 50,51,108. Similarly, glutamine starvation enhances stemness of intestinal organoids
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harboring pre-malignant oncogenic mutations and increases tumor initiating capacity

52

. While

these studies relied on in vitro glutamine starvation, heterogeneity in glutamine availability may
also be an important determinant of cell fate in vivo. For example, glutamine deficiency in
melanoma cores in vivo is sufficient to blunt cancer cell differentiation due to αKG depletion, and
increasing dietary glutamine is sufficient to increase αKG levels and impair tumorigenesis 109,110.
Altogether, these data are consistent with glutamine availability creating a permissive environment
for cell fate determination by enabling αKG accumulation. Thus, anti-cancer therapies aimed at
suppressing glutamine uptake and catabolism may inadvertently select for the most aggressive
stem cells in a tumor.
Conversion of glutamate to αKG is largely accomplished by transaminase enzymes in
proliferating cells, which reversibly donate the amine nitrogen of glutamate to a ketoacid in order
to synthesize a non-essential amino acid (NEAA) and αKG 107. Emerging evidence suggests that
which particular transaminases predominantly contribute to αKG may vary in a tissue-specific
manner. In IDH wild-type AML, catabolism of the branched chain amino acids (BCAA) valine,
leucine and isoleucine by branched chain aminotransferase 1 (BCAT1) restricts intracellular αKG
levels, leading to DNA hypermethylation and HIF1α stabilization. Notably, BCAT1 loss blunts
AML stem cell growth and induces myeloid differentiation

111

. Interestingly, normal HSCs are

reliant on valine for their maintenance for unknown reasons 112. BCAAs are essential and therefore
their uptake is required by all cells for protein synthesis, but BCAT activity may be cell-type
specific

113

. It is therefore intriguing to consider that valine supports HSC self-renewal by

restricting intracellular αKG.
In other tissues, serine synthesis represents a notable source of nucleocytosolic αKG
production via phosphoserine aminotransferase (PSAT1) activity. In breast cancer,
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hyperactivation of the serine synthesis pathway maintains hypoxic breast cancer cell survival and
supports αKG production for TCA cycle anaplerosis 114,115. In this thesis, I show that in the murine
epidermis, in vivo restriction of serine and its immediate downstream metabolite glycine triggers
de novo serine synthesis activation in epidermal stem cells and accumulation of αKG, which is
necessary and sufficient to drive stem cell differentiation, H3K27me3 demethylation, and tumor
suppression 14. Intriguingly, dietary serine and glycine restriction has proven effective in delaying
tumorigenesis in other models as well, and it will be of interest to understand whether or not αKGdependent stem cell differentiation plays a role in these systems116,117. Collectively, these studies
demonstrate that dietary manipulation of extracellular nutrient availability is sufficient to regulate
stem cell fate in part by controlling intracellular αKG levels.

1.8. CONCLUSIONS
Proper development and adult tissue function requires careful control over cell fate
programs. Collectively, the above studies suggest that metabolites act as both inductive signals
and regulators of competence during cell fate determination, and thus disruption of tissue specific
pathways that maintain TCA cycle homeostasis promotes pathology, most notably by enforcing
progenitor self-renewal and driving tumorigenesis.

Metabolite abundances—determined by

environmental nutrient availability and cell-type specific genetic programs—can collaborate
closely with lineage specific transcriptional programs to regulate cell fate. Evidence across
multiple tissues suggest a model wherein αKG acts as an inducer of cell fate changes, while
succinate, fumarate and 2HG largely restrict competence to appropriately execute cell fate
programs. Accordingly, nutrients that fuel intracellular αKG pools create permissive environments
for cell fate decisions, and mutations that drive oncometabolite accumulation prevent αKG-

25

mediated cell decisions. The roles of specific oncometabolites in lineage-specific cancers warrants
investigation into the role of αKG during development and differentiation of their normal tissue
counterparts. More broadly, whether the tissue specific profiles of cancer-associated mutations in
chromatin modifying enzymes such as TETs and DNA and histone methyltransferases likewise
predict metabolite-responsive nodes co-opted by tumors will be an important area of future
investigation.
Future studies should be aimed at better dissecting the roles of specific dioxygenases in
responses to metabolites and the cell-type specific roles of metabolites within native tissue
microenvironments. In particular, whether or not the availability of endogenous nutrients
fluctuates sufficiently to modulate intracellular metabolite abundances and cell fate outcomes
remains to be explored. Finally, although many studies support the role of metabolic changes
regulating cell fate decisions, relatively few studies address whether or not basal metabolism
supports the maintenance of cell-type specific gene expression outputs and accordingly, the
maintenance of cell identity. For example, do transcription factors require a basal level of αKG to
sustain cell identity once a cell’s chromatin landscape is established, or do changes in αKG pools
only enable dynamic reprogramming of gene expression? Improved technologies to enable
measurement of extracellular, subcellular and cell-type specific metabolite abundances in vivo,
coupled with genetic experiments to modulate dioxygenase sensitivity to metabolites, will
facilitate our ability to gain a deeper understanding of the physiological and pathological roles of
metabolites in controlling cell fate.
In this thesis I explore the role of nutrient availability and αKG-dependent dioxygenases
in epithelial stem cells of the skin epidermis. The skin houses an abundant reservoir of stem cells
which maintain distinct tissues within the organ. These include the stem cells of the interfollicular
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epidermis (IFE), which maintain the skin barrier that is essential for maintaining organismal water
and electrolyte balance while protecting us from external infectious and noxious agents, and those
of the hair follicle (HF) which regenerate the hair coat of mammals.
Epithelial stem cells of the skin give rise to malignancies include squamous cell
carcinomas (SCCs) and basal cell carcinomas (BCCs) and are additionally required for wound
repair3. While many foundational studies have identified the core signaling and transcriptional
machinery involved in skin stem cell homeostasis and pathology118, the metabolic determinants of
stem cell behavior in the skin remain largely unexplored. In particular, while recent studies have
highlighted the importance of metabolic pathways such as glucose uptake and glycolysis in
supporting skin stem cell proliferation119,120, little is known about whether or not particular
metabolites regulate stem cell identity or the balance of fate decisions in the skin. I explore the
role of nutrient availability in regulating stem cell fate during SCC initiation as well as epidermal
growth and differentiation. These studies establish extracellular nutrient availability as
determinants of epidermal stem cell fate via control of αKG-dependent dioxygenases.
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CHAPTER 2
EXTRACELLULAR SERINE CONTROLS EPIDERMAL STEM CELL FATE AND
TUMOR INITIATION
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2.1. INTRODUCTION
Stem cells (SCs) maintain tissue homeostasis by balancing self-renewal and
differentiation3. With age, SCs can acquire cancer-associated mutations and clonally expand in the
context of a grossly normal tissue121–125. How SCs contend with pre-malignant oncogenic
mutations, and the mechanisms that ultimately drive a subset of progenitors to initiate neoplasms,
remain largely unknown. The answers become increasingly important given evidence that SCs,
but not terminally differentiated cells, are a major root of malignancy126–129, and that driving SC
differentiation is a potent tumor suppressive mechanism130–133. Thus, identifying factors that
regulate oncogenic SC fate is critical to delineating the mechanisms that drive tumor initiation.
The innermost (basal) layer of mammalian epidermis houses an abundant reservoir of SCs
responsible for maintaining the skin barrier. Acquisition of oncogenic mutations predisposes
epidermal stem cells (EpdSCs) to initiate benign tumors, which progress to squamous cell
carcinomas (SCCs), among the most common cancers worldwide3. As such, the epidermis is an
excellent model to understand the mechanisms regulating pre-malignant SC behavior.
During SCC pre-malignancy, epigenetic and/or genetic mechanisms lead to induction of
the transcription factor SOX2, which is necessary for tumor initiation and progression134–136.
Ectopic activation of SOX2 in EpdSCs induces a stress response involving global protein synthesis
repression and selective translation of oncogenic transcripts135,137. Since protein synthesis is
intimately tied to amino acid availability138, this prompts the intriguing but unexplored hypothesis
that SCs may adapt to oncogenic stress by altering their metabolism.
Increasing evidence suggests that metabolites can regulate SC proliferation, self-renewal
and differentiation13,21,29,119,139. Additionally, metabolic reprogramming supports bioenergetic and
anabolic reactions that are necessary for proliferation21, rendering tumor progression sensitive to
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nutrient availability116,117,140. However, it remains unknown whether oncogenic lesions rewire
endogenous metabolic programs in SCs, and if so, how this contributes to tumor initiation. Here,
I assessed the consequences of oncogenic stress to EpdSC metabolism and discovered that
metabolic reprogramming suppresses differentiation programs that otherwise antagonize
tumorigenesis. These results hold promise for therapeutic avenues targeting oncogenic SCs.

2.2. RESULTS
2.2.1. Pre-malignant SC growth is dependent upon extracellular serine.
Sustained SOX2 expression in EpdSCs induced pre-tumorigenic lesions marked by
hyperproliferation, expansion of K14+ progenitors, and induction of the tumor stem cell (tSC)
marker CD44 (Fig 2.1a). To explore the metabolism of pre-malignant EpdSCs prior to the onset
of hyperproliferation, I crossed R26-LSL-Sox2-IRES-eGFPfl/fl and Krt14-Cre+/wt mice to generate
littermate wild-type (WT) and SOX2+ animals, where Sox2 was induced developmentally in K14+
epidermal progenitors135,141 (Fig. 2.1b). At postnatal day 4 (P4) and in primary culture, SOX2+ and
WT EpdSCs proliferated comparably (Fig. 2.1b,c), enabling us to identify metabolic changes
associated with pre-malignancy independently of hyperproliferation.
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Figure 2.1. SOX2 induction as a model of pre-malignancy in epidermal stem cells. a,
Representative immunofluorescence of progenitor markers a6 and K14, tumor SC markers CD44
and SOX2, and EdU incorporation in P65 WT and SOX2+ mice two weeks after tamoxifen
administration. b, EdU incorporation into integrin-a6+ EpdSCs in P4 WT and SOX2+ mice. c,
Growth of independently derived WT-1,2,3 and SOX2+-1,2,3 EpdSC cultures.
Like SCC-SCs, SOX2+ EpdSCs decrease protein synthesis relative to WT EpdSCs135,137.
Since amino acids provide the majority of cellular biomass142, I asked whether pre-malignant
EpdSCs have altered amino acid requirements. Gas chromatography-mass spectrometry (GC-MS)
of medium from primary cultures revealed that essential amino acids were consumed at similar
rates between WT and SOX2+ EpdSCs (Fig. 2.2a). Of the non-essential amino acids, only
glutamine, tyrosine and serine were appreciably consumed, consistent with reports in cancer
cells142. Of these, only serine was differentially consumed (Fig. 2.2a,b).
Unexpectedly, despite reduced translation135, SOX2+ cells consumed more serine than WT
cells. Glycine, which can be interconverted with serine by serine hydroxymethyltransferases
(SHMT1/2), was not appreciably consumed (Fig. 2.2b). These results suggested that SOX2+
progenitors deviated from WT EpdSCs in serine metabolism. Culturing EpdSCs with uniformly
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13

C-labeled serine confirmed that SOX2+ cells derived a larger portion of intracellular serine from

extracellular sources (Fig. 2.2c).
I next analyzed the consequences of withdrawing extracellular serine from the culture
medium. To minimize possible confounding effects arising from converting glycine to serine under
starvation conditions, I also removed glycine. When deprived of exogenous serine and glycine
(Ser/Gly), SOX2+ cells did not maintain intracellular serine pools as well as WT EpdSCs and their
proliferation halted (Fig. 2.2d,e). By contrast, WT EpdSCs proliferated normally. Ser/Gly
dependence was independent of the oncogene used to induce pre-malignancy, as HRasG12Vexpressing EpdSCs also required exogenous Ser/Gly to proliferate (Fig. 2.2f). These data indicate
that oncogenic EpdSCs rely upon exogenous Ser/Gly to sustain proliferation.
The proliferative block of pre-malignant EpdSCs upon Ser/Gly deprivation was surprising,
given that both can be synthesized de novo143. To determine whether synthesis of one or both
amino acids was defective in SOX2+ cells, I depleted each individually. Consistent with minimal
net consumption of glycine (Fig. 2.2b), glycine deprivation did not affect proliferation. By
contrast, serine starvation alone inhibited SOX2+ proliferation comparably to combined Ser/Gly
deprivation (Fig. 2.2g). Thus, pre-malignant EpdSCs are functional serine auxotrophs that rely
upon obtaining serine from extracellular sources to proliferate. To avoid potential confounding
effects of serine deprivation alone, I starved cells of both Ser/Gly in subsequent experiments.
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Fig 2.2. Pre-malignant EpdSCs are serine auxotrophs. a, b, Gas chromatography-mass
spectrometry (GC-MS) of conditioned medium relative to control medium NEAA indicates nonessential amino acids that are consumed. c, 4 hour fractional labeling of intracellular serine from
[U-13C]serine. d, GC-MS of intracellular serine pools following 16 hours of ser/gly starvation. e,
f, Growth during 48 hours of ser/gly starvation. g, Growth during 48 hours in indicated medium.

In addition to extracellular consumption, cells can derive serine either from SHMT1/2, or
from the serine synthesis pathway (SSP), wherein glucose-derived 3-phosphoglycerate (3PG) is
converted to serine through the sequential enzymes phosphoglycerate dehydrogenase (PHGDH),
phosphoserine transaminase (PSAT1) and phosphoserine phosphatase (PSPH) (Fig. 2.3a). SOX2+
and WT cells exhibited comparable SHMT1/2 expression and Ser/Gly interconversion (Fig.
2.3b,c). Similarly, SOX2+ cells exhibited no defect in SSP enzyme expression upon Ser/Gly
deprivation. However, labeling with [U-13C]glucose revealed reduced glucose-derived serine
synthesis in SOX2+ EpdSCs (Fig. 2.3d). Upon Ser/Gly starvation, WT cells derived the majority
of their intracellular serine from glucose, while SOX2+ cells failed to do so (Fig. 2.3e). Thus, premalignant EpdSCs suppress glucose-dependent serine synthesis.
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Fig. 2.3. Pre-malignant EpdSCs suppress glucose-derived serine synthesis. a, Schematic of
intracellular serine sources. b, Western blot for enzymes that catalyze serine synthesis from either
glucose or glycine following 24 hours of ser/gly starvation. c, 4 hour labeling of serine from
glycine (left) or glycine from serine (right). d, 4 hour fractional labeling of serine from glucose. e,
4 hour labeling of serine from glucose following 16 hours of ser/gly starvation.
2.2.2 Limited cytosolic NAD+ regeneration drives serine auxotrophy
I next assessed why SOX2+ cells did not employ the SSP. Downstream of the serine
precursor 3PG, the glycolytic end-product pyruvate can either be shunted to lactate or enter
mitochondria to fuel the tricarboxylic acid (TCA) cycle. Pyruvate enters the TCA cycle either
through pyruvate dehydrogenase (PDH) or pyruvate carboxylase (PC) to fuel citrate production
(Fig. 2.4a).
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Isotope tracing revealed that SOX2+ cells increased glucose-derived citrate synthesis
through both PDH and PC (Fig. 2.4b), indicating that pre-malignant EpdSCs were not generally
defective in glucose metabolism. SOX2+ cells demonstrated increased expression of pyruvate
carboxylase (Pcx) and pyruvate dehydrogenase E1b (Pdhb) transcripts, suggesting a coordinated
program favoring mitochondrial pyruvate consumption (Fig. 2.4c). I therefore asked whether
increasing mitochondrial pyruvate metabolism conferred serine auxotrophy. Increasing pyruvate
oxidation in WT EpdSCs with dichloroacetate (DCA)144 induced serine auxotrophy (Fig. 2.4d).
Conversely, blocking mitochondrial pyruvate import using UK-5099145 conferred resistance to
serine starvation (Fig. 2.4e). These results suggest that elevated mitochondrial pyruvate utilization
can induce dependence on exogenous serine.

35

Fig. 2.4. Glucose oxidation drives serine auxotrophy. a, Schematic of glucose metabolism in
glycolysis and the TCA cycle as well as associated inhibitors. b, 4 hour fractional labeling of citrate
isotopologues from glucose. m+0 represents citrate that was not labeled by glucose, m+2 and m+3
represent PDH and PC derived citrate, respectively. Higher order (m+4, m+5, m+6) represent
subsequent turns around the TCA cycle. c, qPCR for key pyruvate fate enzymes. d-e, Cell count
following 48 hours of culture in indicated conditions. f, Mechanisms of action of AKB. g, Growth
of cells during 48 hours of culture in indicated conditions. h, Cell count following 48 hours of
culture in indicated conditions.
Once imported into mitochondria, pyruvate is no longer a substrate for cytosolic lactate
dehydrogenase, which reduces pyruvate to lactate to regenerate oxidized NAD+ required for
glycolysis. As NAD+ is also a cofactor for the rate-limiting SSP enzyme PHGDH146, I
hypothesized that enhanced mitochondrial pyruvate metabolism of SOX2+ cells limits cytosolic
NAD+ regeneration, thereby impairing the SSP. Consistent with this hypothesis, a-ketobutyrate
(AKB), an alternative LDH substrate that enables NAD+ regeneration147 rescued serine
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auxotrophy in both SOX2+ and DCA-exposed WT cells (Fig. 2.4f-h). Furthermore, the
pyruvate/lactate ratio, which varies in concert specifically with the cytosolic NAD+/NADH
ratio148,149, was lower in SOX2+ cells compared to WT cells (Fig. 2.5a,b). Supplementing pyruvate
to increase the NAD+/NADH ratio147,150 supported increased lactate secretion and rescued serine
auxotrophy in SOX2+ cells (Fig. 2.5c-e). Conversely, lowering the NAD+/NADH ratio with lactate
supplementation induced auxotrophy in WT EpdSCs (Fig. 2.5e).
Genetic interventions to manipulate the NAD+/NADH ratio produced similar results.
Expression of LbNOX, a bacterial NADH oxidase148, increased the whole-cell NAD+/NADH
ratio, increased [U-13C]glucose labeling of serine, and rescued serine auxotrophy of both SOX2+
cells and lactate-treated WT cells (Fig. 2.5f-j). Collectively, these findings indicate that cytosolic
NAD+ regeneration controls serine biosynthesis in EpdSCs.
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Fig. 2.5 Cytosolic NAD+ Regeneration Dictates Serine Auxotrophy. a, Schematic of pyruvate
mechanism of action. b, GC-MS quantifaction of the pyruvate/lactate ratio. c, Lactate secretion
during 24 hours of culture in indicated medium. d, Intracellular serine pools in SOX2+ cells
following 16 hours in indicated medium. e, Growth during 48 hours of culture in indicated
medium. f, Mechanism of action of LbNOX. g, Immunofluorescence validating expression of
LbNOX. h, Quantification of whole cell NAD+/NADH ratio. i, 4 hour fractional labeling of serine
in SOX2+ cells following 16 hours of ser/gly starvation. j, Growth during 48 hours of culture in
indicated medium.
2.2.3. Serine restriction induces differentiation of wild-type EpdSCs
My findings thus far demonstrate that serine auxotrophy distinguishes pre-malignant
EpdSCs from their normal counterparts. To understand how serine availability affects EpdSC
function in vivo, I assessed the effects of dietary Ser/Gly withdrawal116,117 on EpdSC growth and
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differentiation, which must be balanced to maintain homeostasis. I placed pregnant mice on a
Ser/Gly-free diet (Fig. 2.6a) and analyzed littermate WT and SOX2+ animals at P0. The diet neither
induced apoptosis in either genotype, nor affected WT EpdSC proliferation; in contrast, Ser/Gly
restriction impaired SOX2+ EpdSC proliferation (Fig. 2.6b,c). This effect was likely cell
autonomous, as culturing EpdSCs with low levels of Ser/Gly to mimic dietary restriction
specifically slowed growth of SOX2+ EpdSCs (Fig. 2.6d). Reduced proliferation of SOX2+
EpdSCs in low Ser/Gly conditions was accompanied by a failure to induce the SSP and sustain
intracellular serine pools (Fig. 2.6e,f). Similar to my in vitro findings, SOX2+ EpdSC proliferation
in vivo was rescued by enhancing NAD+ regeneration via in utero transduction of epidermal
progenitors151 with LbNOX (Fig. 2.6g).
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Fig. 2.6 Pre-malignant EpdSCs are in vivo serine auxotrophs. a, Serum serine and glycine
levels of female mice maintained on a control or ser/gly free diet for 2 weeks. b, EdU incorporation
in P0 mice on a control or ser/gly free diet. c, Immunofluorescence of cleaved caspase 3 in P0
mice on a control or ser/gly free diet. d-f, In vitro growth (d), intracellular serine pools (e) and 4
hr fractional labeling of serine from glucose (f) upon 50% reduction of extracellular ser/gly levels.
g, Schematic (left) and analysis (right) of EdU incorporation in EpdSCs of mice transduced with
LbNOX, comparing transduced and untransduced EpdSC proliferation in the same mice.
Notably, despite maintaining proliferation (Fig. 2.6), WT epidermis on a Ser/Gly-free diet
displayed marked thickening of the differentiating layers, typified by expression of Involucrin and
Keratin-10 (K10) (Fig. 2.7a). Epidermal differentiation is driven by asymmetric cell divisions of
basal stem cells, in which the division axis of EpdSCs is perpendicular to the basement membrane,
such that one daughter cell leaves the basal layer to generate a suprabasal cell committed to
terminal differentiation152. Consistent with increased differentiation, epidermal thickening in WT
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mice on a ser/gly free diet was accompanied by an increase in EpdSCs dividing perpendicularly to
the basement membrane (Fig. 2.7b). To directly assess whether extracellular Ser/Gly starvation
prompted EpdSCs to differentiate prematurely, I utilized a transgenic reporter mouse wherein the
Krt10 promoter drives H2B-mRFP, thereby marking induction of a terminal differentiation
program153. Strikingly, Ser/Gly restriction significantly increased the proportion of prematurelydifferentiated Krt10-H2B-mRFP+ EpdSCs (Fig. 2.7c). By contrast, SOX2+ EpdSCs maintained
planar cell divisions and showed no increase in differentiation (Fig. 2.7b,c).
To determine whether the effect of Ser/Gly depletion on differentiation was cellautonomous, I measured SC (Krt14 and Krt5) and differentiation (Lor and Flg) gene expression in
vitro. Consistent with our in vivo results, Ser/Gly depletion repressed Krt14/K5 and increased
Lor/Flg expression specifically in WT EpdSCs (Fig. 2.7d). Partial Ser/Gly restriction and serine
starvation alone yielded similar results (Fig. 2.7e,f). Collectively, these data suggest that Ser/Gly
availability regulates the balance between EpdSC growth and differentiation, and that oncogenic
EpdSCs are resistant to Ser/Gly deprivation-induced differentiation.
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Fig 2.7 Serine starvation drives WT EpdSC differentiation. a, Thickness of terminally
differentiated cell layers of P0 mice. b, Representative classes (left) and quantification (right) of
cell division angles of P0 mice based on the angle of the midbody marker Survivin relative to the
basement membrane. SB = suprabasal. c, Quantification of the differentiation reporter Krt10-H2BmRFP in P0 mice. d, qPCR of key stem cell and differentiation genes following 24 hours of ser/gly
starvation in vitro. e-f, Immunofluorescence (e) and quantification (f) of the stem cell marker K14
following 24 hours of culture in indicated condition. g, Immunofluorescence and quantification of
the stem cell marker following 24 hours of culture in indicated condition.
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2.2.4. De novo serine synthesis in EpdSCs promotes a-ketoglutarate-dependent
differentiation
A priori, differentiation could be due to either serine depletion per se or induction of the
SSP via one of its byproducts, NADH or a-ketoglutarate (aKG) (Fig. 2.8a). To uncouple these
possibilities, I knocked down Phgdh, the first SSP enzyme. Phgdh suppression blocked precocious
differentiation induced by serine restriction, suggesting that SSP flux, rather than serine depletion,
drives epidermal differentiation (Fig. 2.8b-e).
I next asked which byproduct of the SSP promoted precocious differentiation. NADH
seemed unlikely, as interventions that favor NADH oxidation (either AKB or UK5099), promoted,
rather than inhibited, differentiation (Fig. 2.8f). By contrast, exogenous cell-permeable aKG was
sufficient to induce differentiation in both WT and SOX2+ EpdSCs (Fig. 2.9a). Moreover, aKG
restored differentiation in Phgdh-deficient WT EpdSCs, underscoring its ability to trigger the
consequences of SSP activation (Fig. 2.8d,e).
Indeed, Ser/Gly starvation of WT EpdSCs led to accumulation of aKG (Fig. 2.9b).
Importantly, Phgdh silencing blunted aKG accumulation following Ser/Gly restriction (Fig. 2.9c).
Many reactions can generate aKG from glutamine107. Based on calculations of serine and
glutamine uptake in WT EpdSCs, I estimated that approximately 10% of consumed glutamine is
used to sustain serine synthesis during Ser/Gly deprivation (Appendix Table 2.1-2.2).
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Fig 2.8 Glucose-derived serine synthesis drives αKG dependent differentiation. a, Schematic
of serine biosynthesis and its by-products. b, Western blot validating knockdown of PHGDH in
WT EpdSCs expressing either shScramble or shPhgdh hairpins. shPhgdh-1 and shPhgdh-2.2 were
used for subsequent experiments. c, Validation of shPhgdh lines via proliferation (left) and GCMS of intracellular serine pools (right) upon ser/gly starvation. d, Immunofluorescence (top) and
quantification (bottom) of the stem cell marker K14 cultured in indicated conditions for 24 hours.
e, Immunofluorescence (top) and quantification (bottom) of the differentiation marker Involucrin
in indicated conditions for 24 hours. f, Quantification of Involucrin staining in WT (top) or SOX2+
(bottom) EpdSCs following culture in indicated conditions for 24 hours.
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Fig 2.9 αKG is necessary and sufficient for ser/gly starvation induced differentiation. a,
Immunofluorescence of K14 expression in cells cultured with dimethyl (DM)-αKG for 24 hours.
b-c, GC-MS of intracellular αKG following 16 hours of culture. d-e, Immunofluorescence and
analysis of K14 (d) or Involucrin (e) in cells cultured with 1 mM of the one carbon donor formate,
4 mM DM-αKG, or 4 mM DM-succinate for 24 hours.
Interestingly, aKG also affected SOX2+ EpdSCs (Fig. 2.9a), indicating that they are not
generally defective for differentiation. SOX2+ EpdSCs exhibited reduced levels of aKG under
both control and -Ser/Gly conditions (Fig. 2.9b), consistent with impaired SSP activity. Therefore,
I asked whether rescuing aKG levels in these cells could restore differentiation. Indeed, aKG
reversed the differentiation block of Ser/Gly-starved SOX2+ EpdSCs (Fig. 2.9d,e). The ability of
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aKG to restore differentiation was not merely due to its role as an anaplerotic substrate for the
TCA cycle downstream of the SSP154, since cell-permeable succinate, another TCA cycle
intermediated, did not induce differentiation (Fig. 2.9d,e).
In addition to serving as a substrate for the TCA cycle, aKG is also a co-substrate for a
large family of dioxygenases that consume aKG and produce succinate as part of their reaction
cycle8. Succinate, a competitive inhibitor of these enzymes8, was sufficient to block differentiation
induced by Ser/Gly deprivation (Fig. 2.9d,e). Therefore, I hypothesized that Ser/Gly deprivation
induced differentiation by activating aKG-dependent dioxygenases. Metabolic regulation of
aKG-dependent dioxygenases, including the Jumonji-domain family of histone demethylases, has
been implicated in chromatin regulation and cell fate decisions8,21. In the skin, trimethylation of
histone 3 lysine 27 (H3K27me3) represses terminal differentiation gene expression. Accordingly,
EpdSC differentiation is accelerated by conditional loss of Ezh2, an H3K27 methyltransferase, and
inhibited by loss of the aKG-dependent H3K27me3 demethylase JMJD3155,156.
Culturing EpdSCs with cell-permeable aKG revealed that H3K27me3 levels are sensitive
to intracellular aKG levels (Fig. 2.10a). I therefore posited that serine biosynthesis might favor
aKG-dependent H3K27me3 demethylation, and hence differentiation. Indeed when WT EpdSCs
were starved for Ser/Gly or serine alone, H3K27me3 levels decreased (Fig. 2.10b-e). H3K27me3
loss was Phgdh-dependent, and aKG reversed the effects of Phgdh silencing (Fig. 2.10f).
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Fig 2.10 Serine synthesis drives αKG-dependent histone demethylation. a, H3K27me3 levels
in cells cultured with 4mM DM-αKG for 24 hours. b, H3K27me3 levels in EpdSCs of P0 mice. cd, H3K27me3 levels in cells cultured for 24 hours in the indicated medium. e, H3K27me3 levels
in shScramble or shPhgdh WT EpdSCs cultured in the indicated medium with or without 4 mM
DM-αKG for 24 hours. f, H3K27me3 levels in cells cultured in indicated medium with or without
1 mM formate, 4 mM DM-αKG, or 4 mM DM-succinate for 24 hours.
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To directly test the role of H3K27me3 in differentiation induced by Ser/Gly starvation, I
utilized inhibitors against JMJD3 (GSK-J4) and EZH2 (GSK-343) to block H3K27me3
demethlyation or methylation, respectively. GSK-J4 prevented H3K27me3 loss and differentiation
induced by Ser/Gly starvation in WT EpdSCs. Conversely, GSK-343 suppressed H3K27me3 in
both WT and SOX2+ EpdSCs and promoted differentiation (Fig. 2.11).
Ser/Gly starvation can exert pleiotropic cellular effects, including depletion of one-carbon
units that contribute to methylation reactions157 and increased oxidative stress that can drive
epidermal differentiation117,158. However, one-carbon units did not appear to be limiting, since
supplying exogenous formate did not rescue H3K27me3 or differentiation (Fig. 2.9e,f, 2.10f).
Likewise, while antioxidants blocked differentiation, consistent with known roles of ROS in
differentiation158, they neither affected H3K27me3 nor protected against differentiation upon
EZH2 inhibition (Fig. 2.11). In contrast, cell-permeable aKG promoted H3K27me3 demethylation
and differentiation in SOX2+ cells, and cell-permeable succinate suppressed differentiation and
H3K27me3 loss in WT EpdSCs (Fig. 2.9d,e, 2.10f)
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Fig 2.11 Ser/Gly induced differentiation is driven by H3K27me3 demethylation. a, b,
Immunofluorescence (a) and quantification (b) of H3K27me3 and K14 in cells cultured in
indicated medium for 24 hours with the antioxidants esterified reduced glutathione (eGSH) or the
vitamin E analog Trolox, the EZH2 inhibitor GSK343 or the JMJD3/UTX inhibitor GSKJ4. c, d,
Immunuofluorescence (c) and quantification (d) of H3K27me3 and K14 in cells cultured for 24
hours in indicated medium with GSH, GSK343, or both.

51

52

Taken together, our data suggest that endogenous serine synthesis poises EpdSCs to
differentiate by facilitating H3K27me3 demethylation, although additional aKG-dependent
dioxygenases may contribute to epidermal differentiation. Moreover, SSP suppression enables premalignant EpdSCs to escape differentiation and enforce self-renewal.

2.2.5. Ser/Gly starvation impairs tumor initiation and growth
The finding that Ser/Gly starvation induced differentiation led us to posit that Ser/Gly
deprivation might impair tumor initiation. To investigate this possibility, I placed mice on a
Ser/Gly-free diet prior to administration of a classical chemical carcinogenesis protocol, in which
mice are administered a single dose of 7,12-dimethylbenz[a]anthracene (DMBA) followed by
twice weekly 12-O-tetradecanoylphorbol-13-acetate (TPA), that leads to initiation of EpdSCderived benign papillomas and malignant SCCs159 (Fig. 2.12a). Compared to a control diet,
Ser/Gly starvation significantly impaired tumor initiation and reduced tumor burden (Fig. 2.12b).
Similar results were obtained upon orthotopic injection of established SCCs into
immunocompromised (Nude) mice (Fig. 2.12c).
Tumor growth under dietary Ser/Gly starvation requires enhanced SSP activity17,116. Based
upon our data, I hypothesized that SSP activation might also
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Fig 2.12 Dietary ser/gly restriction impairs tumor initiation and growth. a, Schematic of
DMBA/TPA model of SCC initiation. b, Tumor free survival curve (left), tumor burden (center)
and representative mice (right) in DMBA/TPA treated mice. c, Tumor growth of established SCCs
injected intradermally. d-e, H3K27me3 levels in DMBA/TPA (d) and established SCC allografts
(e). f-g, K14 and K10 staining (f) and quantification (g) in DMBA/TPA induced tumors. h, K10
staining in SCC allografts grown in mice treated with GSK-J4.
represent a liability for SCCs by driving differentiation. Indeed, tumors that formed under the
selective pressure of Ser/Gly restriction exhibited reduced H3K27me3 and enhanced
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differentiation, typified by reduced K14 and increased K10 staining, relative to controls (Fig.
2.12d-g). Pharmacologically inhibiting aKG-dependent H3K27me3 demethylases160 prevented
starvation-induced differentiation (Fig 2.12g).
Ser/Gly starvation also induced differentiation, H3K27me3 loss, and growth suppression
in xenografts of human A431 and SCC9 lines (2.13a-f). Finally, analysis of 139 different cutaneous
and head and neck human SCCs revealed that H3K27me3 levels correlated with SCC grade (Fig.
2.13g). Thus, my findings identify a strong link between Ser/Gly availability, H3K27me3
demethylation and tSC fate.
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Fig 2.13 Human SCCs are sensitive to ser/gly restriction. a-c, K14/K10 staining (a),
H3K27me3 staining (b) and growth (c) in A431 SCC xenografts. d-f, K14/K10 staining (d),
H3K27me3 staining (e), and growth (f) in SCC9 SCC xenografts. g, Correlation of H3K27me3
IHC with histopathological tumor grade in cutaneous SCCs (cSCC) and head and neck SCCs
(HNSCC).
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2.2.6. Glucose-derived serine synthesis suppresses tumorigenesis and stemness
To determine whether the anti-tumor effects of Ser/Gly starvation are due to Ser/Gly
starvation or SSP activation, I silenced Phgdh in SCCs (Fig. 2.14a,b). In vivo, Phgdh silencing
prevented H3K27me3 loss upon Ser/Gly starvation (Fig. 2.14c). Consistent with driving
differentiation, Ser/Gly starvation induced tSC depletion, as reflected by loss of cells expressing
the tSC markers CD44 and SOX2. Silencing Phgdh expanded the tSC pool and prevented tSC loss
upon dietary Ser/Gly starvation (Fig. 2.14d,e). Critically, SCC differentiation required an intact
serine synthesis pathway, since Phgdh silencing blocked diet-induced differentiation, as assessed
by K14/K10 staining (Fig. 2.14f,g).
These findings suggested that, in contrast to previous reports on melanoma and breast
cancer154,161, cell-autonomous SSP activation acts as a tumor suppressor in SCCs by driving SC
depletion. Consistent with tSC expansion, shPhgdh SCCs grew more rapidly than shScramble
SCCs under normal growth conditions in vivo (Fig. 2.15a). Importantly, I could abrogate this
advantage by putting shPhgdh SCCs on a Ser/Gly-free diet, which suppressed shPhgdh SCC
proliferation (Fig 2.15b,c). Phgdh ablation using CRISPR-Cas9 likewise enhanced tumor growth
(Fig 2.15d-f). Together, these results underscore the advantage that SCC-SCs gain by silencing
endogenous serine biosynthesis so long as exogenous serine is present to fulfill anabolic demands.
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Fig 2.14 Glucose-derived serine synthesis suppresses SCC stem cell maintenance. a, Western
blot (left) and growth during 48 hours of ser/gly starvation (right) of shPhgdh mouse SCC lines.
b, Immunofluorescence of H3K27me3 levels in shPhgdh orthotopic allografts. c-d,
Immunofluorescence of the stem cell markers CD44 (c) and SOX2 (d) in shPhgdh orthotopic
allografts. e-f Immunofluorescence of K14 (e) and K10 (f) in shPhgdh orthotopic allografts.

59

Fig 2.15. Glucose derived serine synthesis suppresses tumorigenesis when extracellular
serine is available. a, Growth of shPhgdh orthotopic allografts on a control diet. b-c,
Immunofluorescence (b) and analysis (c) of Ki67 staining, a marker of proliferation, in shPhgdh
allografts under control and ser/gly free diet conditions. d, Growth of shPhgdh allografts under
control and ser/gly free diet conditions. e-f, validation of PHGDH KO lines. sgPhgdh lines A1 and
sgPhgdh C6 were used for subsequent experiments and are referred to as sgPhgdh-1 and sgPhgdh6, respectively. g, Growth of sgPhgdh orthotopic allografts.
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2.2.7. αKG drives tumor suppression and differentiation in SCCs
Our data suggest that by inducing the SSP, the consequential production of aKG can bias
tSCs to differentiation and thereby suppress tumorigenesis. To directly test this model, I
manipulated intracellular aKG and succinate by engineering SCC cells to silence either
oxoglutarate dehydrogenase (Ogdh) which consumes aKG, or succinate dehydrogenase A (Sdha),
which consumes succinate (Fig. 2.16a)53. As expected, intracellular aKG was increased in shOgdh
lines while succinate was increased upon Sdha silencing (Fig. 2.16b).
While each hairpin reduced tumor growth on a normal diet, they had opposing effects upon
Ser/Gly restriction (Fig. 2.16c). OGDH loss hampered SCC growth and was sufficient to drive
H3K27me3 loss and tumor differentiation, as assessed by K14/K10 staining, even on a normal diet
(Fig. 2.16d-f). This was not due to TCA cycle disruption, as SDHA loss failed to induce
differentiation in control mice (Fig. 2.20e,f). Rather, SDHA silencing prevented both H3K27me3
loss and differentiation upon Ser/Gly restriction (Fig. 2.16d-f). As a result, shSdha tumors
sustained growth in the absence of dietary Ser/Gly (Fig. 2.16c). Collectively, these findings are
consistent with Ser/Gly starvation inducing activation of aKG-dependent dioxygenases that
promote tumor suppressive differentiation programs.
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Fig 2.16. αKG is necessary and sufficient for SCC differentiation. a, Schematic of the TCA
cycle highlighting reactions catalyzed by OGDH and SDHA. b, GC-MS of intracellular αKG (left)
and succinate (right) levels in shRenilla, shOgdh, and shSdha SCC lines, verifying expected
changes in metabolite abundance upon knockdown. c, Growth of indicated SCC lines injected
orthotopically. d, H3K27me3 immunofluorescence of indicated SCC lines. e-f, Quantification (e)
and immunofluorescence (f) of differentiation in indicated SCC lines, as assessed by K14/K10
staining.
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2.3. DISCUSSION
In this study I discovered that environmental serine availability profoundly affects tumor
initiation and SC fate. Pre-malignant EpdSCs that are destined to initiate tumors suppress de novo
serine synthesis by increasing mitochondrial pyruvate consumption, resulting in endogenous
serine auxotrophy. In WT EpdSCs, SSP activation facilitates aKG accumulation, which favors
H3K27me3 demethylation and promotes terminal differentiation. The SSP also regulates SCC
differentiation. In the presence of abundant serine, SSP inhibition triggered expansion of tSCs and
promoted tumor growth. Conversely, enforcing serine synthesis using a Ser/Gly-free diet impaired
tumor initiation in mice. Diet-mediated tumor suppression could be reversed by inhibiting aKGdependent dioxygenases, underscoring aKG-dependent differentiation as a major route of tumor
suppression. These findings are likely to have relevance to humans, since xenografts were sensitive
to Ser/Gly starvation and H3K27me3 levels correlated positively with tumor grade in human
SCCs. These results shed light on how SCs integrate nutrient availability with chromatin dynamics
in vivo (Fig 2.17). This work was recently published in Nature Cell Biology14.
Recent evidence supports my finding that NAD+ regeneration is limiting for serine
biosynthesis146. Previous studies revealed that environmental or genetic manipulations that impose
mitochondrial redox imbalances subsequently impair amino acid biosynthesis146,147,150. Here, I find
that endogenous changes in central carbon metabolism, such as those found in SOX2+ EpdSCs,
similarly impair cytosolic NAD+ regeneration and amino acid biosynthesis. Collectively, these
findings suggest that compartment-specific redox metabolism is likely to be an important regulator
of cell fate decisions and nutrient stress responses. Although I cannot rule out the possibility that
other mechanisms may restrict serine synthesis in pre-malignant EpdSCs, our data support a
critical role for cytosolic NAD+ regeneration in regulating serine auxotrophy and EpdSC behavior.
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Fig 2.17 Extracellular serine controls epidermal stem cell fate and tumor initiation. Summary
model of metabolic control of tumor initiation. Serine auxotrophy enforces oncogenic stem cell
self-renewal but suppressing serine synthesis-derived αKG, which otherwise drives demethylation
of H3K27me3, enabling expression of terminal differentiation genes.

Emerging evidence suggests that extracellular Ser/Gly restriction impairs tumor growth by
imposing redox stress116,117 and limiting one-carbon units that support proliferation162. My data
extend the tumor suppressive effects of Ser/Gly deprivation to tumor initiation, while providing
an additional mechanism by which Ser/Gly restriction can antagonize tumorigenesis. The degree
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to which Ser/Gly restriction affects endogenous serine synthesis, aKG production, and
differentiation programs in other cell types is an important area for future investigation.
Intriguingly, certain cancers harbor recurrent mutations in metabolic enzymes that poison
aKG-dependent dioxygenases to suppress differentiation30,31,38,163. My data illustrate that even in
the absence of such mutations, tSCs rewire intrinsic metabolic pathways to antagonize aKGdependent chromatin remodeling. While I cannot exclude regulation of other aKG-dependent
dioxygenases, I find that environmental Ser/Gly availability contributes to H3K27me3
demethylation, an established mediator of epidermal differentiation.
In conjunction with recent data that mutational status53, nutrient availability97,109,164 and
other metabolic pathways165 can suppress aKG-dependent dioxygenases, our work supports the
notion that aKG may act generally as a metabolic tumor suppressor. The pathways that contribute
to aKG pools may vary in a cell-type and context-specific manner154,164,165. It is intriguing to
consider that while the TCA cycle produces aKG in mitochondria, the SSP generates aKG in the
nucleo-cytosolic compartment, where it can act directly as a co-substrate for aKG-dependent
dioxygenases. More broadly, my findings expose a way in which SCs balance metabolic demands
for growth with those of regulating cell identity.
Consistent with recent work17,116, I find that the SSP is critical for growth when
extracellular serine is limiting. However, when extracellular serine is abundant, I find that the SSP
is tumor suppressive. By contrast, certain established cancers including breast cancer and
melanoma rely on SSP flux to maintain proliferation even in the presence of abundant extracellular
serine154,161. Intriguingly, some of these tumors have evolved mechanisms such as EZH2
overexpression166 to suppress differentiation. Thus, plentiful exogenous serine may generally
support tumor initiation and growth both by repressing differentiation and supporting proliferation.
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A key question from this work is how SCs are able to initiate a tumor in the face of serine
auxotrophy. Both normal and malignant SCs reside in proximity to the vasculature, and the
perivascular niche is critical for maintaining tSC self-renewal167,168. It is therefore tempting to
speculate that this niche also represents a rich nutrient source that enables tumorigenic SCs to rely
on extracellular serine and suppress differentiation. Dietary Ser/Gly restriction disrupts SC
maintenance, thereby establishing serine availability as a key regulator of cell fate during tumor
initiation and growth. These findings raise the possibility that targeting serine uptake may be a
promising therapeutic avenue to eliminate oncogenic stem cells by blunting their self-renewal and
growth.
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CHAPTER 3
PERSPECTIVES AND FUTURE DIRECTIONS
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3.1 INTRODUCTION
Stem cells balance decisions of self-renewal and differentiation to maintain tissue
homeostasis, and imbalances in this decision drive diverse pathologies including cancer and aging.
Although numerous signaling and transcriptional pathways have been linked to stem cell fate
regulation, the role of nutrients and metabolites in controlling stem cell behavior has been
relatively less well explored. Moreover, whether or not endogenous metabolic pathways control
key stem cell functions such as tumor initiation and lineage plasticity are poorly understood. Using
the mammalian epidermis as a model system, I have explored these questions throughout the
course of my thesis.
In particular, I have focused on how availability and uptake of the nutrient serine is linked
to intracellular metabolic pathways that control abundance of the metabolite αKG, a critical cosubstrate for chromatin modifying enzymes. I found that starving EpdSCs of serine triggers
activation of the serine synthesis pathway, which drives αKG accumulation that is necessary and
sufficient for epidermal differentiation and H3K27me3 demethylation. Accordingly, I found that
serine availability controls the ability of a stem cell to initiate a neoplasm and properly respond to
tissue injury. Finally, pre-malignant EpdSCs suppress endogenous serine synthesis to support their
own self renewal. These findings have implications for therapeutic targeting of stem cells that
initiate and sustain tumors and for enhancing wound repair. In this chapter I discuss three
outstanding questions raised by my studies: the role of transporters in stem cell biology; the role
of compartmentalized redox metabolism in controlling cell fate; and the mechanisms by which
αKG might regulate stem cell fate.
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3.2 METABOLITE TRANSPORTERS AS REGULATORS OF STEM CELL FATE
Both in vitro and in vivo, I have found that limiting extracellular serine drives changes in
stem cell behavior. In EpdSCs and SCC-SCs, it drives differentiation; in pre-malignant EpdSCs it
drives growth arrest; and in HFSCs it promotes lineage plasticity. Moreover, measurements of
serine uptake demonstrated that pre-malignant EpdSCs increased serine uptake relative to WT
EpdSCs. These studies point to a critical role of serine abundance in mediating stem cell behaviors.
In particular, in the IFE, it is tempting to speculate that the balance of extracellular serine
abundance and intracellular serine uptake is an endogenous driver of EpdSC differentiation, such
that differentiation is coupled to enhanced serine synthesis-dependent αKG production.
Within a tissue, abundance of a nutrient that a cell experiences is likely determined by two
key parameters: non-autonomous control by tissue vasculature (supply) and cell autonomous
control by transporter expression (consumption). First, proximity of a cell to and structure of the
vasculature is likely to be a key determinant of nutrient availability, since the vasculature delivers
and drains nutrients and oxygen to and from a tissue169,170. In the skin, stem cells reside on the
basement membrane and are therefore in close proximity to blood and lymphatic vasculature.
These vascular niches have been implicated in stem cell proliferation and self-renewal in the skin,
although their role in regulating nutrient homeostasis has not been well explored91,167,168. Despite
this, manipulation of the vasculature is likely to have pleiomorphic effects beyond nutrient
regulation, given the critical role of perivascular niche in signaling to stem cells90,167,168.
Nevertheless, the epidermis itself is avascular, and therefore it is likely that EpdSCs have greater
access to nutrients than their differentiated counterparts due to their proximity to the vasculature.
Secondly, nutrients are taken up into cells by transporters on the plasma membrane.
Accordingly, it is tempting to speculate that transporter expression could determine the relative
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abundance of a nutrient that a cell experiences, both based on the affinity of a particular transporter
for its substrate and the amount of transporter a cell expresses. This effect has been well
documented for glucose, where expression of the low affinity glucose transporter GLUT2 in
metabolic organs enables sensing of circulating glucose levels to control systemic glucose
homeostasis171. Moreover, acute regulation of GLUT1 plasma membrane localization enables
rapid increases in glucose uptake upon growth factor stimulation88. Whether or not similar
paradigms of nutrient sensing exist for other metabolites, such as serine, remains largely
unexplored, and the role of transporters in controlling stem cell biology is not well understood.
Serine is thought to be transported into cells by Solute Carrier Family 1A4 (SLC1A4) and
1A5 (SLC1A5), both of which use sodium ion co-transport to drive uptake172,173. Serum serine
levels are approximately 200±100 µM, and the Michaelis constants (an enzymatic measure of
affinity) of SLC1A4 and SLC1A5 for serine are 100±20 µM and 250±40 µM, respectively172–174.
Accordingly, SLC1A4 is predicted to be a high affinity serine transporter relative to SLC1A5 (Fig.
3.1a). Given increased serine uptake in pre-malignant SOX2+ EpdSCs relative to WT EpdSCs, I
asked whether or not this might be linked to differential expression of serine transporters.
Consistent with its role as a high affinity serine transporter, I found that SOX2+ EpdSCs expressed
higher levels of Slc1a4 mRNA and protein in vitro (Fig. 3.1b). Intriguingly, in vivo, SLC1A4
expression is restricted to EpdSCs within both WT and SOX2+ epidermis, although its expression
remains higher in SOX2+ EpdSCs (Fig. 3.1c). That SLC1A4 is only expressed in stem cells within
the epithelium raises the possibility that differentiation is endogenously coupled to a decrease in
serine uptake and an increase in serine synthesis, driving αKG-dependent differentiation.
Importantly, serine itself is an essential metabolite for epidermal barrier formation due to its role
in sphingolipid biosynthesis175,176, suggesting that differentiation would impose a significant

72

demand for serine synthesis in the absence of the ability of differentiated cells to consume serine
from extracellular sources. Consistently, patients with PHGDH deficiency exhibit impaired
epidermal differentiation that is associated with defects in sphingolipid biosynthesis176,177.

Fig. 3.1 SLC1A4 as a putative regulator of EpdSC fate. a, Enzymatic parameters of SLC1A4
and SLC1A5, two potential serine transporters. b, mRNA (left) and Western blot (right) of serine
transporters in cultured EpdSCs. c, In vivo SLC1A4 expression. Dashed line indicates basement
membrane, solid line indicates air-epithelial interface. d, Potential model for how serine
availability and transport endogenously regulate epidermal differentiation.
Altogether, the combination of EpdSC proximity to the vasculature and restricted
expression of SLC1A4 suggests a model wherein apparent serine availability endogenously
controls epidermal differentiation (Fig. 3.1d). This would be consistent with our data that dietary
Ser/Gly restriction increases EpdSC differentiation. Future studies should be aimed at
manipulation of SLC1A4 to determine its role in epidermal differentiation, both via loss of
function studies and overexpression of SLC1A4 mutants with varying affinities for serine173 in
differentiating cells. Reconstitution of SLC1A4 in cultured WT EpdSCs as well as cell free studies
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will enable us to interrogate its biochemical function as a serine transporter in the epidermis. If
SLC1A4 expression determines differentiation, I might expect that its overexpression in
suprabasal cells would block their differentiation via suppression of serine synthesis dependent
αKG production, while maintaining sphingolipid synthesis.
More broadly, given the restricted nature of SLC1A4 expression it is intriguing to consider
whether or not a “transporter code” exists within tissues, such that the cohort of transporters
particularly cell types express determines their function and fate. Moreover, transporters are
appealing therapeutic targets given their plasma membrane localization and the possibility of
developing competitive inhibitors for their substrates. Altogether, my functional studies on
extracellular Ser/Gly restriction in Chapter 2 coupled with preliminary expression data presented
here warrant further investigation of amino acid transporters as critical regulators of physiological
stem cell functions.

3.3. COMPARTMENTALIZED REDOX METABOLISM AS A REGULATOR OF CELL
FATE.
A major contribution of my work is the identification of cytosolic redox status as a
determinant of serine synthesis in EpdSCs. Briefly, the first step of serine synthesis by PHGDH
requires the reduction of NAD+ to NADH. Accordingly, sustaining serine synthesis requires a
mechanism to regenerate NAD+ from NADH in the cytosol, which in most cells is accomplished
via the conversion of pyruvate to lactate by lactate dehydrogenase178. I found that pre-malignant
EpdSCs restricted serine synthesis by decreasing the conversion of pyruvate to lactate, instead
oxidizing pyruvate in the TCA cycle. Notably, increasing NAD+ regeneration was sufficient to
drive stem cell differentiation, presumably in part by enhancing serine synthesis. Interestingly, in
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the intestinal crypt, blocking pyruvate entry into the mitochondria and subsequently shunting it to
lactate enhances stem cell proliferation and self-renewal179–181. These studies provide evidence that
compartmentalized redox status is a lineage specific determinant of cell fate and nutrient
dependencies.
Previous studies have linked redox status to amino acid biosynthesis. Of note, these studies
found that genetic and pharmacological suppression of mitochondrial NAD+ regeneration was
sufficient to impair aspartate and serine biosynthesis146,147,150,182. Our work, in contrast, is the first
demonstration of endogenous metabolic rewiring via changes in pyruvate fate controlling redox
homeostasis. Moreover, they place these previous findings in the physiological context of tumor
initiation and stem cell fate and provide evidence for distinct functions of cytosolic and
mitochondrial redox homeostasis. Studying the role of redox metabolism in other physiological
stem cell functions such as during wound healing may be of interest for future studies.
I suggest that in part, enhancing cytosolic NAD+ regeneration drives differentiation by
enhancing αKG synthesis via serine synthesis. Future studies can take advantage of LbNOX
expression, which I established and validated in the epidermis, to genetically enhance NAD+
regeneration in order to further investigate this process. Moreover, LbNOX can also be targeted to
the mitochondria (mitoLbNOX)148, and comparative analysis of the effects of mitoLbNOX and
LbNOX may enable us to understand the physiological functions of compartmentalized redox
metabolism in EpdSCs. It will be of particular interest to understand whether or not there are αKGindependent effects of cytosolic NAD+ regeneration on stem cell fate, such as through regulation
of nucleotide synthesis or transcriptional co-repressors183–186.
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3.4 αKG AS A REGULATOR OF STEM CELL FATE IN THE EPIDERMIS
I found that extracellular serine abundance controls stem cell fate by regulating αKG levels.
Limiting extracellular Ser/Gly triggers activation of the serine synthesis pathway, which
subsequently leads to αKG accumulation that can drive EpdSC differentiation and H3K27me3.
These studies build on previous work from our lab and others showing that the H3K27me3
methyltransferase EZH2 is essential for EpdSC self-renewal and that the demethylase JMJD3 is
essential for differentiation155,156,187. Nevertheless, as discussed in Chapter 1, it remains
challenging to understand how αKG mediates specific effects, given that multiple intracellular
dioxygenases consume it as part of their reaction cycle. Indeed, although I find that
pharmacological inhibition of JMJD3 is sufficient to reverse Ser/Gly starvation induced
differentiation, and that H3K27me3 levels correlate with αKG-induced differentiation, it remains
possible that additional dioxygenases are important in differentiation. For example, similar to
H3K27me3, DNA methylation has been shown to be critical for EpdSC self-renewal188, suggesting
that TET enzymes that demethylate DNA may also play a role in αKG-dependent differentiation.
Nevertheless, this work is the first to establish αKG as a regulator of adult stem cell behavior,
building on work in embryonic stem cells that αKG is a key determinant of stem cell fate29.
Multiple cancers harbor recurrent mutations in metabolic enzymes, such as isocitrate
dehydrogenase 1 and 2 (IDH1/2) and succinate dehydrogenase (SDH) that result in accumulation
of so-called oncometabolites that poison αKG-dependent dioxygenases. Notably, these
oncometabolites largely function by locking stem cells in a hyperproliferative self-renewing
state21. Consistently, αKG has been shown to suppress tumorigenesis and drive differentiation in
multiple cancers including leukemia, pancreatic cancer, and intestinal cancer52,53,111. Thus, our
work adds to a growing body of literature suggesting that αKG acts as a metabolic tumor
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suppressor. Additionally, it is consistent with previous work showing that environmental
constraints such as glutamine limitation and hypoxia can limit αKG-dependent dioxygenase
function52,97,109, suggesting that cancer cells can engage multiple mechanisms to evade the tumor
suppressive effects of αKG. Moreover, it provides evidence that stem cells can rewire endogenous
metabolic pathways to limit αKG production, such that even under serine limited conditions premalignant EpdSCs can prevent differentiation by suppressing serine synthesis.
An important question is understanding whether or not it will be feasible to enhance αKG
production to suppress tumorigenesis. While this represents an appealing route forward, it should
be noted that αKG accumulation may not always be beneficial. For example, in breast cancer, αKG
promotes metastatic colonization of the lung by enhancing activity of αKG-dependent collagen
hydroxylases164. In pediatric ependymomas, αKG was recently shown to be critical in establishing
epigenomic programs that support proliferation104. These studies highlight the importance of
understanding the specific mechanisms by which αKG mediates its diverse effects, so as to better
refine our ability to target this critical metabolic axis.

3.5 CONCLUSIONS
In this thesis, I aimed to explore metabolic control of stem cell function in the skin. In
doing so, I uncovered the mechanisms by which nutrient availability is integrated with stem cell
fate decisions during tumor initiation and progression and wound repair. I anticipate that these
findings will have implications beyond the skin. It may be of particular interest to study the links
between αKG and amino acid uptake in stem cells that initiate neoplasms driven by IDH mutations,
such as those of the blood and brain. Additionally, I anticipate that understanding the links between
endogenous metabolic pathways and transcriptional programs in stem cells will be broadly
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relevant in pathologies outside of cancer, including inflammatory diseases, wound healing,
diabetes and degenerative diseases. Finally, building on our knowledge of the mechanisms by
which serine, αKG and cell fate are linked will enable directed therapies to enhance epidermal
wound repair while suppressing tumorigenesis.
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MATERIALS AND METHODS
Cell culture. Primary EpdSCs from WT and SOX2+ mice, HRasG12V transduced EpdSCs, and SCC lines
were grown under standard tissue culture conditions, 37 oC and 7.5% CO2. Cells were cultured in E-low
calcium (50 μM Ca2+) medium (E-low) made in house from DMEM/F12 medium supplemented with 15%
chelated FBS, 5 μg/mL insulin, 5 μg/mL transferrin, 2 nM triiodothyroxine, 40 μg/mL hydrocortisone and
10 nM cholera toxin. For all experiments, cells were switched from E-low growth medium to E-low lacking
pyruvate, aspartate, glutamate, and glutamine reconstituted with 4 mM glutamine, 25 mM glucose, 15%
chelated dialyzed FBS (GeminiBio), and ±0.32 mM Ser/Gly (experimental E-low medium). A431 SCCs
were grown in DMEM supplemented with 10% FBS and 1 mM sodium pyruvate. SCC9 SCCs were grown
in E-low medium supplemented to 1.5 mM Ca2+. A mix of male and female cells were used for all studies.
Independently derived littermate lines were used for comparisons. Unless noted in legends, WT-1 and
SOX2-1 lines were used.
Mice. All animal experiments were performed in the AAALAC-accredited Comparative Bioscience Center
at the Rockefeller University. Experiments were in accordance with NIH guidelines for Animal Care and
Use, approved and overseen by The Rockefeller University’s Institutional Animal Care and Use Committee.
Rosa26-CAG-loxP-stop-loxP-Sox2-IRES-eGFP mice were donated by J. Que and maintained in a
B6/svev129 mixed background. Krt14-cre(tg), Krt14-creER(tg), and Krt10-H2B-mRFP(tg) mice were
maintained in a CD-1-ICR background. Sox9-CreER;R26-LSL-YFP mice were maintained in a mixed
B6/CD1 background. For analysis of WT and SOX2+ mice, a mix of males and females were used. Krt14CreER;R26-LSL-Sox2-IRES-GFP and Sox9-CreER;R26-LSL-YFP mice were treated with 5 100 μL doses
of 2% w/v tamoxifen (Sigma) beginning at P50. For tumor allografts, 6-8 week old female Nude (Nu/Nu)
mice were used. For DMBA/TPA experiments, P60 female FvB mice were used.
Primary culture derivation. P0 mice were euthanized by decapitation, backskin was dissected off and
incubated in a 1:1 mix of dispase and PBS overnight at 4 oC. Epidermis was removed from the dermis and
incubated in a 1:1 mix of 0.25% trypsin/EDTA and versene for 10 min at room temperature. The epidermal
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fraction was mechanically dissociated to a single cell suspension, filtered through a 40 μm filter and
cultured in E-low medium.
Growth curves. 5000 WT, SOX2+ or HT-SCC cells were plated in triplicate into a black 96 well plate
(Nunc). The next day (day 0), one plate was fixed with 4% PFA for 10 min. Remaining cells were treated
with indicated medium/reagent, and at indicated times were subsequently fixed, stained with DAPI, and
counted using a BioTek Cytation5. For chemical treatments, cells were pre-treated for 4 h prior to switching
to control or serine/glycine (Ser/Gly)-free experimental E-low medium. For partial Ser/Gly starvation
experiments, cells were cultured in medium with 17.065 mg/L serine and 12.19 mg/L glycine. Population
doublings were calculated as the log2 fold change in cell number relative to day 0.
Scratch wound. HFSCs were seeded in a 6 well plate. When cultures were confluent, cells were washed
once with PBS and switched into control or ser/gly free medium. A P200 pipet tip was dragged once down
the length of each well to generate a wound, and cells were imaged using phase contrast microscopy and
indicated time points.
In vitro drug treatments. Drugs were added at the following concentrations: a-ketobutyrate 1 mM,
dichloroacetate 5 mM, UK-5099 500 nM, pyruvate 2 mM, lactate 2 mM, formate 1 mM, dimethyl-aketoglutarate 4 mM, 4 mM, eGSH 1 mM, Trolox 500 nM, GSK-J4 10 µM, GSK-343 10 µM, Nutlin-3a 10
µM.
Nutrient uptake. 150,000 WT or 300,000 SOX2+ cells were seeded into 6 well plates (Corning). The
following day, medium was aspirated and replaced with 1 mL of experimental E-low medium containing
Ser/Gly. At the same time, 1 mL of medium was added to a control 6 well plate lacking cells. 24 h later,
media was collected and spun at max speed at 4 oC for 20 min. 50 µL of the supernatant was added to 1 mL
of ice-cold 80% methanol supplemented with 2 μM deuterated 2-hydroxyglutarate (D-2-hydroxyglutaric2,3,3,4,4-d5 acid (d5-2HG)) as an internal standard and analyzed by mass spectrometry. Glutamine
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consumption, glutamate secretion and lactate secretion were measured using a YSI 2950 series
biochemistry analyzer (YSI Life Sciences). Metabolite consumption and secretion was determined relative
to fresh medium and the values were normalized to the average protein content in each condition where
indicated.

Serine standard curve. Serine (0-20 nmol) was dissolved in 50 μL of water and mixed with ice-cold 80%
methanol supplemented with d5-2HG. After overnight incubation at -20°C, the serine standards were dried
in an evaporator (Genevac EZ-2 Elite), derivatized as described in GC-MS metabolite profiling and
analyzed using an Agilent 7890A GC coupled to Agilent 5975C mass selective detector. A standard curve
was obtained by plotting d5-2HG-normalized serine peak area against the amount serine. The linear
regression equation was calculated by the least squares method using Microsoft Excel.

Estimation of serine synthesis. To quantify the amount of serine consumption, the MS peaks representing
serine were extracted and integrated using MassHunter software, normalized to the internal standard (d52HG) peak area and quantified against the serine standard curve. The calculated values were normalized to
the average protein content of all wells in each condition (µmol serine/mg protein). Serine biosynthetic
demand in the absence of exogenous Ser/Gly was estimated using a serine standard curve to calculate serine
uptake (from Fig. 1c) in the presence of Ser/Gly and serine secretion in the absence of Ser/Gly, while
intracellular glutamine availability was estimated using a YSI analyzer as glutamine consumption minus
glutamate secretion. Since serine synthesis produces a mole of aKG per mole of serine, the fraction of
intracellular glutamine used to meet serine biosynthetic demand approximates the fraction of glutamine
used to produce aKG via this pathway. See Supplementary Tables 2 and 3 for more information.

GC-MS metabolite profiling. For all metabolite experiments, 150,000 WT or 300,000 SOX2+ cells were
seeded in 6-well plates under standard culture conditions and changed into the corresponding experimental
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E-low media the next day. For isotope tracing experiments, cells were cultured for 4 h in indicated
experimental E-low medium reconstituted with uniformly labeled 13C-serine, glycine, glucose or glutamine
(Cambridge Isotope Labs) following 16 hours of culture in experimental E-low medium with or without
Ser/Gly. For serum, blood was collected from the retro-orbital sinus and allowed to clot on ice for 30 min.
Samples were then spun at 1,000 g for 10 min and supernatant (serum) was collected. Metabolites were
extracted with 1 mL of ice-cold 80% methanol supplemented with d5-2HG.
After overnight incubation at -80°C, cell lysates were centrifuged at 21,000 g for 20 min and protein-free
supernatants were dried in an evaporator (Genevac EZ-2 Elite). Metabolites were resuspended in 50 μL of
40 mg/mL methoxyamine hydrochloride (Sigma) in pyridine (ThermoFisher) by incubation at 30°C for 2
h and further derivatized by addition of 80 μL of MSTFA (ThermoFisher) and 70 μL ethyl acetate (Sigma).
After 30 min incubation at 37°C, samples were analyzed using an Agilent 7890A GC coupled to Agilent
5975C mass selective detector. The GC was run in splitless mode using constant helium gas flow at 1
mL/min. A microliter of derivatized sample was injected onto an HP-5MS column and the GC oven
temperature ramped from 60°C to 290°C over 25 min.
GC-MS analysis. Peaks representing metabolites of interest were extracted and integrated using
MassHunter software (Agilent Technologies) and verified relative to known spectra for each metabolite.
The following ions were used for quantification of metabolite levels: d5-2HG m/z 354; alanine, m/z 218;
aKG, m/z 304; asparagine, m/z 231; aspartate, m/z 334; citrate, m/z 465; cysteine, m/z 322; fumarate, m/z
245; glutamate, m/z 363; glutamine, m/z 362; glycine, m/z 276; isoleucine, m/z 260; leucine, m/z 260;
malate, m/z 335; methionine, m/z 250; phenylalanine, m/z 294; proline, m/z 216; serine m/z 306; succinate,
m/z 247; threonine, m/z 320; tryptophan, m/z 405; tyrosine, m/z 382; and valine, m/z 246; pyruvate, m/z 115;
lactate m/z 219. All values were normalized to both the internal standard peak area and the protein content
of triplicate samples. Enrichment of 13C was determined by quantifying the abundance of the following
ions: citrate, m/z 465-482; glycine, m/z 276-286; and serine, m/z 306-317. Correction for naturally occurring
isotopes was performed using IsoCor software189.
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NAD+/NADH ratio quantification. The NAD+/NADH ratio was quantified using an enzymatic
colorimetric Abcam kit according to manufacturer’s instructions. Briefly, cells were lysed with 450 µL
NADH/NAD extraction buffer and then spun for 5 min at 4oC at maximum speed. Supernatant was filtered
through a 10 kDa spin column (BioVision) and 200 µL was used for total NAD+ and NADH quantification.
The remaining extract was heated at 60oC for 30 min to decompose NAD+. 50 µL of sample was mixed
with 100 µL of reaction mixture and incubated for 5 min at room temperature. 10 µL of developing solution
was added and the reaction was incubated for 1 h at room temperature. Absorbance was measured at 450
nm using a BioTek Cytation 5 plate reader and NAD+ and NADH amounts were calculated using a standard
curve of purified NADH. The NAD+/NADH ratio was calculated as (NAD(H)total – NADH)/NADH.
Immunofluorescence and image analysis. For immunofluorescence, samples were dissected off of mice,
were pre-fixed in 4% PFA for 1 h at 4°C and then incubated with 30% w/v sucrose overnight, embedded in
Optimal Cutting Temperature (OCT) compound (Tissue Tek), and sectioned at a thickness of 12 μm. For
in vitro immunofluorescence, cells were seeded into fibronectin coated glass chamber-slides (Millipore),
and fixed for 10 min in 4% PFA at room temperature. To determine HFSC proliferation in waxing
experiments, skin was scraped to remove fat, incubated in 2.5 U/mL dispase + 20 mM EDTA for 2 hr at
37oC, and then HFs were separated from the epidermis manually. Samples were blocked at room
temperature in Gelatin Block (2% fish gelatin, 5% normal donkey serum, 1% bovine serum albumin, 0.3%
Triton, in PBS). Samples were incubated with primary antibody overnight at 4°C, washed in PBS, and
exposed to secondary antibody for 1 h at room temperature. Samples were mounted in ProLong Gold with
DAPI (Life Tech) prior to imaging. The following primary antibodies and dilutions were used: GFP
(chicken, 1:2000, Abcam), GFP (goat, 1:1000 VWR), K5 (guinea pig, 1:500, E. Fuchs), K10 (rabbit,
1:1000, Covance), RFP (rat, 1:1000, Chromotek), RFP (goat, 1:500, MYBioSource), K14 (rabbit, 1:1000,
E. Fuchs), K14 (chicken, 1:1000, Covance), Involucrin (rabbit, 1:1000, Covance), SOX2 (rabbit, 1:300,
Abcam), cleaved caspase 3 (rabbit, 1:200, Cell Signaling), integrin-a6 (rat, 1:2000, eBioscience),
H3K27me3 (rabbit, 1:500, Millipore), FLAG M2 (mouse, 1:1000, Sigma), CD44 (rat, 1:200, BD
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Bioscience), Ki-67 (rabbit, 1:200, Cell Signaling), K24 (Fuchs lab, 1:5000), KLF5 (goat, 1:100, R&D),
SLC1A4 (rabbi, 1:200, Cell Signaling). Secondary antibodies were conjugated to Alexa FluorTM 488, RRX,
or 647 (1:1000, Life Technologies A-11006). Phalloidin conjugated to Alexa FluorTM 564 or 647 (165 nM
working concentration, ThermoFisher) were used and stained simultaneously with secondary antibodies.
Images were captured on a Zeiss Axioplan2 using a Plan-Apochromat 20x/0.8 air objective or 40x/0.8 oil
immersion objective. Images were processed using ImageJ and Adobe Photoshop CS5. See Reporting
Summary for antibody catalog numbers.
To quantify fluorescence in SCCs of progenitor and differentiated cell markers, tumor cells were masked
on GFP (for K14, K10 and involucrin) or DAPI/H2B-mRFP (for H3K27me3) and pixel intensity was
analyzed within the mask on the marker of interest. In the absence of a mask for cells of interest,
fluorescence was quantified manually through ROI selection. To quantify mitotic spindle axis, a straight
line was drawn between the middle of two daughter nuclei marked by K14, and the angle between this line
and the basement membrane, as stained by keratin-14, was quantified. Mitotic angles < 30o were classified
as planar, and angles >30o were classified as nonplanar.
Immunohistochemistry. All human samples were derived from commercially purchased, de-identified
paraffin embedded tissue arrays (Biomax SK802b, HN803e). Arrays were baked at 60oC for 30 min and
then deparaffinized by washing 2x10 times in Citrus Clearing Solvent (ThermoFisher) followed by 2x10
washes in 100% ethanol (EtOH), 1x10 wash in 95% EtOH, and 1x10 wash in 70% EtOH. Antigen retrieval
was then performed in pH 6.0 Citrate (Vector Laboratories) by heating slides to 125oC for 30 s and 90oC
for 10 s in a pressure cooker. Slides were stained according to VECTASTAIN® Elite® ABC Universal
PLUS Kit manufacturer instructions (Vector Laboratories). Briefly, slides were permeabilized for 5 min in
0.1% TBS-T, blocked in BLOXALL peroxidase block for 10 min and horse serum for 20 min. Arrays were
incubated in primary antibody (H3K27me3 rabbit, 1:500, Millipore) overnight at 4oC. The next day, slides
were incubated with secondary antibody (Horse anti-mouse/rabbit IgG, biotinylated) for 30 min at room
temperature. Slides were incubated in VECTASTAIN Elite ABC Reagent for 30 min at room temperature,
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and then in a 1:1 mixture of ImPACT® DAB EqV Reagent 1 (Chromogen) and Reagent 2 (Diluent) for 2
min. After development, slides were incubated in hematoxylin (Sigma) for 1 min, washed 3x in water,
washed 1x in acid alcohol (1% HCl in 95% EtOH), washed 3x in water, washed 1x in Bluing Reagent
(Fisher), washed 1x in water, and then dehydrated by washing 10x 70% EtOH, 10x 95% EtOH, 2x10 100%
EtOH, 2x10 Citrus Clearing Solvent. Slides were mounted with Cytoseal 60 (ThermoFisher). Images were
captured using a BioTek Cytation 5 using a 4x or 20x air objective. See Reporting Summary for antibody
catalog numbers.
To score arrays for H3K27me3 intensity, investigators were blinded to tumor stage, lineage and anatomic
location. Within a tissue core, lymphocytes were used as an internal control for high H3K27me3 staining.
Staining intensity within tumor cells was scored “high” if intensity was at least ~70% as intense as
lymphocytes, “moderate” if intensity was ~30-70% as intense as lymphocytes, or “weak” if staining was
<30% as intense as lymphocytes. After scoring, investigators were unblinded to bin scoring results based
on histopathological grade. Images were processed in ImageJ and Photoshop.
Hematoxylin & eosin. Slides were washed in water, incubated in hematoxylin for 2 min, washed in water
3x, washed once in acid alcohol, washed twice in water, washed once in Bluing reagent, and washed once
in water. Slides were subsequently dehydrated with 10 washes each in subsequent 80%, 95% and 100%
EtOH, followed by eosin staining for 1 minute, 2 x 20x washes in 100% EtOH and 2 x 20x washes in Citrus
Clearing Solvent. Slides were mounted with Cytoseal 60 and imaged on a Zeiss Axioplan2 using a PlanApochromat 20x/0.8 air objective. Images were processed in ImageJ and Photoshop.
Western Blot. Triplicate wells were lysed in chilled RIPA buffer containing cOmplete protease inhibitors
and PhoSTOP phosphatase inhibitors (Roche). Protein was quantified using a Pearce BCA protein
quantification kit. 15 μg of protein was loaded for SDS-PAGE and standard western blotting procedures.
For histone extraction, 1 x 106 cells were suspended in Laemmli buffer and sonicated 15X, 30 s on/off. bmercaptoethanol and bromophenol blue were added, samples were boiled, and 6 µL was loaded for standard
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western blotting procedures. Membranes were blocked in LiCOR blocking buffer. Membranes were
incubated in primary antibody overnight in blocking buffer with 0.2% Tween-20 at 4oC, and incubated in
secondary antibody diluted in blocking buffer with 0.2% Tween-20 and 0.01% SDS for 1 h at room
temperature. The following primary antibodies and dilutions were used: PHGDH (rabbit, 1:2000, Sigma),
PSAT1 (mouse, 1:500, Sigma) PSPH (rabbit, 1:500, Sigma), SHMT1 (rabbit, 1:1000, Cell Signaling),
SHMT2 (rabbit, 1:1000, Cell Signaling), OGDH (rabbit, 1:1000, ProteinTech), SDH-A (mouse, 1:1000,
abcam), H3K27me3 (rabbit, 1:1000, Millipore), a-tubulin (mouse, 1:10000, Sigma), total H3 (mouse,
1:10000, abcam), b-actin (rabbit, 1:1000, Cell Signaling), SLC1A4 (rabbit, 1:1000, Cell Signaling). The
following LiCOR secondary antibodies were used, all at 1:10000: IRDye 800CW donkey anti-mouse IgG,
IRDye 800CW donkey anti-rabbit IgG, IRDye 680 LT donkey anti-mouse IgG, IRDye 680LT donkey antirabbit IgG. Membranes were imaged via fluorescence on an Odyssey CLx Imager and processed using
Adobe Photoshop CS5. See Reporting Summary for antibody catalog numbers.
qRT-PCR. Triplicate wells were lysed in 200 µL TRIzol. RNA was extracted using a Zymo Direct-zol
RNA miniprep kit, and 100 ng of RNA was used for cDNA synthesis with a SuperScript VILO cDNA
synthesis kit (ThermoFisher). cDNA was diluted 1:5 for qPCR. cDNAs were mixed with indicated genespecific primers listed in Supplementary Table 7 and SYBR green PCR Master Mix (Sigma), and qRTPCR was performed on an Applied Biosystems 7900HT Fast Real-Time PCR system. Values were
normalized to expression of b-actin.
EdU incorporation. Mice were treated with 0.02 CC of 5 mg/mL EdU for 1 hour prior to sacrifice. EdU
staining was performed following incubation of slides with secondary antibody. AF-647 azide, copper
sulfate and EdU additive buffer and reaction buffers (Life Technology) were added to slides. Slides were
incubated for 20 min at room temperature, washed and mounted for imaging.
Tumor allograft, xenograft and growth curves. 200,000 mouse (HrasG12V;Tgbr2 cKO) or human (SCC9,
or A431) SCC cells diluted 1:1 in growth factor-reduced, phenol red-free Matrigel (Corning) were injected
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intradermally into the backs of Nude mice. For shSdha and shOgdh experiments, mice were treated with
100 mg/L doxycycline and 2% w/v sucrose in drinking water starting 5 days after grafting. For GSK-J4
treatment, mice were treated daily for five days intraperitoneally with 10 mg/kg GSK-J4, beginning 5 days
after grafting. For rapamycin treatment, mice were treated daily for five days intraperitoneally with 4 mg/kg
rapamycin, beginning 5 days after grafting. Tumors were measured at indicated time points. Tumor size
was measured using a digital caliper, and volume was calculated using the formula (π(length x width)2)/6.
Serine/glycine free diet. Purified control amino acid diet (5CC7) and diet lacking serine and glycine
(5BJX) (WF Fisher and Sons) were formulated as previously described116,117. Mice were maintained on
diets for at least two weeks prior to initiating experiments. Pregnant females were placed on diet on the day
of plug.
DMBA/TPA two step chemical carcinogenesis protocol. P60 female WT FvB mice were placed on
control or serine/glycine free diet. Two weeks later, mice were treated topically with a single 100 µL dose
of 400 nmol DMBA (Sigma) diluted in acetone. Beginning the following week, mice were treated 2x/week
topically with 100 µL of 20 nmol TPA (Sigma) diluted in ethanol and monitored for tumors.
Wounding. Second telogen mice were used for wounding experiments. Mice were anesthetized with
isofluorane and shaved for partial thickness and full thickness wounds. For partial thickness wounding, skin
was gently stretched and a Dremel tool with a polishing tool was used to make abrasions of the epidermis
by polishing the skin 4-5 times (100 series rotary tool and 520 polishing tool from Dremel Inc.). For full
thickness wounding, a 6 mm punch biopsy (Miltex) was taken. For depilation, molten wax was applied onto
the hair coats and peeled off after hardening.
CRISPR/Cas9 editing of SCC cells. Guide RNA (gRNA) targeting the second and fourth exons of Phgdh
were designed using GuideScan software70. Synthetic gRNAs, negative control gRNA, Atto550-trRNA,
and recombinant Cas9 were purchased from IDTdna. gRNA:trRNA:Cas9 complexes were assembled and
transfected into SCC cells following manufacturers protocol (IDTdna.com: Cationic lipid delivery of
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CRISPR ribonucleoprotein complexes into mammalian cells) using RNAiMAX (ThermoFisher) reagent as
the transfection reagent. 48 h post transfection single GFP+/Atto550+/DAPI- cells were sorted into 96 well
plates and allowed to grow into clonal cell lines. To screen cells for Phgdh knockout, genomic DNA was
isolated from each clone. Short PCR amplicons including the gRNA target region were generated, barcoded,
sequenced in a multiplex fashion on an Illumina MiSeq Nano using a modified version of the 16S
metagenomics sequencing library preparation protocol from illumima. Knockout was confirmed by
western blot. sgRNA sequences are provided in Supplementary Table 6.
shRNA mediated knockdown and viral infection. Following Phgdh hairpin screening via transient
transfection, efficient hairpins were subcloned into pLKO-H2B-mRFP1 vectors. shOgdh and shSdha
hairpins were packaged into LT3-GEPIR doxycycline inducible vectors53 (donated by S. Lowe) and
validated following culture of cells in 1 µg/mL doxycycline hyclate (Sigma) for 24 h. For LbNOX
expression, LbNOX-Flag (Addgene #75285) was amplified and subcloned with an N-terminal P2A site into
pLKO-H2B-mRFP1. Vectors were packaged into lentivirus using calcium chloride transfection of 293TN
cells (Invitrogen) with packaging plasmids pMD2.G and pPAX2 (Addgene #12259 and #12260,
respectively). Viral supernatant was collected 46 h after transfection and filtered through a 0.45 μm filter.
Cells were then transduced and two days later were purified using fluorescence associated cell sorting
(FACS) based on mRFP1 expression. For shRenilla, shOgdh, and shSdha lines, infected cells were selected
using 1 µg/mL puromycin for 24 h. shRNA sequences are provided in Supplementary Table 5.
Statistics and Reproducibility
Statistical analyses were performed using Prism 7 and 8 (Graphpad) software. All in vitro experiments
shown were repeated at least twice in triplicate with similar results, and representative data are shown unless
otherwise indicated. All in vivo experiments were repeated in at least three biological replicates with similar
results. Unpaired two-tailed Student’s t-tests were used to ascertain statistical significance between two
groups. One-way ANOVA was used to assess statistical significance between three or more groups with
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one experimental parameter, while two-way ANOVA was used to assess statistical significance between
groups with two experimental parameters. See Fig. legends for more information on statistical tests. Mice
were randomly allocated to control or experimental conditions. Experimenters were not blinded to
conditions during data collection or analysis, except for scoring of H3K27me3 staining by IHC, where
investigators were blinded to tumor histological grade.

89

APPENDIX
Table 2.1. Serine standard curve data
Serine (nmol)

D5-2HG normalized peak area
0

0.027213558

0

0.011766296

0.1

0.025398432

0.1

0.028388756

0.5

0.114490747

0.5

0.102225692

1

0.217915223

1

0.251592868

2.5

0.464356491

2.5

0.508034819

5

1.251600614

5

0.850940717

10

2.508784279

10

2.423833354

20

3.985209204

20

4.160433295

Standard curve:

y = 0.212x (R2 = 0.98673)
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Table 2.2. Extracellular glutamine, glutamate and serine data

Parameter

Mean (n = 6)

Standard Deviation

Gln consumption (mmol/mg
protein)

6.439

0.4965

Glu secretion (mmol/mg protein)

1.14

0.02147

Intracellular Gln (Gln consumed
- Glu secreted) (mmol/mg
protein)

5.299

0.4858

Ser consumption (mmol/mg
protein)

0.5164

0.1203

Ser secretion (mmol/mg protein)

0.05072

0.01014

Serine synthesis (Ser
consumption + Ser secretion)
(mmol/mg protein)

0.5671

0.1193

Fraction of Intracellular Gln (Ser
synth/Intracellular Gln)

0.1092

0.03382
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Table 2.3 shRNA sequences
shScramble

CAACAAGATGAAGAGCACCA

shPhgdh-1

CCGAATGCAATCCTTTGGAAT

shPhgdh-2

CGTGAACTTGGTGAACGCTAA

shRenilla

TAGATAAGCATTATAATTCCT

shOgdh-1

TAAATGAAACATTTTGTCCTG

shOgdh-2

TAGCAATTCTGCATACTTCTG

shSdha-1

TTAATTGAAGGAACTTTATCTC

shSdha-2

TTCATAACCGATTCTTCTCCAG

shSdha-3

TCTGATGTTCTTATACTTCCAT
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Table 2.4 sgRNA sequences
sgPhgdh-A

AATGAGGCCTTCACAGTCCT

sgPhgdh-B

CCAGAACTTACTTCATGACT

sgPhgdh-C

TGGCAAATGGGACCGGAAGA
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Table 2.5 RT-qPCR primers
Ldha_F

AGGCTCCCCAGAACAAGATT

Ldha_R

TCTCGCCCTTGAGTTTGTCT

Pdk1_F

GTGCCCCTGGCTGGGTTTGG

Pdk1_R

CCAGGCGTCCCATGTGCGTT

Pcx_F

GGCCAAGGAAAATGGTGTAG

Pcx_R

CTTCC ACCTT GTCTCCCATC

Pdha1_F

ACACAGCATGAGTGACCCTG

Pdha1_R

CACCCATCCACCCACCTAAC

Pdhb_F

TGGTGCTGATGTCCCTATGC

Pdhb_R

CCTTCCAGTGAAAGAGGGCA

Krt-14_F

CGCCGCCCCTGGTGTGG

Krt-14_R

ATCTGGCGGTTGGTGGAGGTCA

Krt-5_F

AACATTTTGGGGTCTGGGTCAC

Krt-F_R

GGCCCACAGAGACTGCTTCTTT

Lor_F

TCACTCATCTTCCCTGGTGCTT

Lor_R

GTCTTTCCACAACCCACAGGA

Flg_F

GGAGGCATGGTGGAACTGA

Flg_R

TGTTTATCTTTTCCCTCACTTCTACATC

Tp53_F

CTAGCATTC AGGCCCTCATC

Tp53_R

TCCGACTGTGACTCCTCCAT
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Cdkn1a_F

CGGTGTCAGAGTC TAGGGGA

Cdkn1a_R

ATCACCAGGATTGGACATGG

Mdm2_F

TGTCT GTGTCTACCGAGGGTG

Mdm2_R

TCCAACGGACTTTAACAACTTCA

Actin_F

GCTCTTTCCAGCCTTCCTT

Actin_R

CTTCTGCATCCTGTCAGCAA
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